image
imagewidth (px) 258
933
| latex
stringlengths 198
5.27k
| filename
stringlengths 18
19
|
|---|---|---|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Vaccine protein} & \textbf{Adjuvant} & \textbf{Log10 cfu/spleen} & \textbf{Unit of protection} & \textbf{P-valuea} \\
\hline
BMEI0357 & CFA/IFA & 4.83 $\pm$ 0.25 & 1.2 & 0.0019 \\
\hline
BMEI1098 & CFA/IFA & 4.57 $\pm$ 0.25 & 1.46 & 0.0009 \\
\hline
BMEI1845 & CFA/IFA & 4.57 $\pm$ 0.25 & 1.46 & 0.0002 \\
\hline
BMEII0346 & CFA/IFA & 4.63 $\pm$ 0.53 & 1.4 & 0.0113 \\
\hline
BMEII0375 & CFA/IFA & 4.53 $\pm$ 0.58 & 1.5 & 0.0119 \\
\hline
BMEII0395 & CFA/IFA & 4.63 $\pm$ 0.50 & 1.4 & 0.0094 \\
\hline
S19 & IFA & 4.26 $\pm$ 0.21 & 1.77 & 0.0003 \\
\hline
PBS & CFA/IFA & 6.03 $\pm$ 0.15 & – & – \\
\hline
\end{tabular}}
\end{table}
|
PMC4625564_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
D—H···A & D—H & H···A & D···A & D—H···A \\
\hline
N2—H2···O3i & 0.86 & 1.96 & 2.809 (2) & 167 \\
\hline
N3—H3B···O1ii & 0.86 & 2.14 & 2.958 (2) & 160 \\
\hline
N3—H3A···N1 & 0.86 & 2.35 & 2.697 (2) & 105 \\
\hline
\end{tabular}}
\end{table}
|
PMC3011812_table_3
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Formula} & & \textbf{Herbs} \\
\hline
SJYJJS & Mulberry leaf & Chrysanthemum & Forsythia suspense & Reed rhizome \\
\hline
& Common hogfennel root & Bitter apricot kernel & Platycodon root & Liquorice \\
\hline
SKT & Mulberry leaf & Fermented soybean & Thunberg fritillary bulb & Radix adenophorae \\
\hline
& White mulberry root-bark & Cape jasmine fruit & Bitter apricot kernel & Liquorice \\
\hline
SJZBY & Mulberry leaf & Chrysanthemum & Thunberg fritillary bulb & Reed rhizome \\
\hline
& Common hogfennel root & Bitter apricot kernel & Platycodon root & Liquorice \\
\hline
\end{tabular}}
\end{table}
|
PMC3594946_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
& & \multicolumn{4}{|l|}{\textbf{Gender}} \\
\hline
& & \multicolumn{2}{|l|}{\textbf{Male}} & \multicolumn{2}{|l|}{\textbf{Female}} \\
\hline
& & \textbf{N} & \textbf{\%} & \textbf{N} & \textbf{\%} \\
\hline
Age Group & $<$ 25 & 98 & 29.5 & 59 & 37.1 \\
\hline
& 25–34 & 104 & 31.3 & 55 & 34.6 \\
\hline
& 35–44 & 81 & 24.4 & 29 & 18.2 \\
\hline
& 45–54 & 37 & 11.1 & 12 & 7.5 \\
\hline
& $>$ 55 & 12 & 3.6 & 4 & 2.5 \\
\hline
Education & Illiterate & 7 & 2.2 & 1 & 0.7 \\
\hline
& Primary school & 41 & 13.1 & 5 & 3.3 \\
\hline
& Secondary school & 133 & 42.5 & 71 & 46.4 \\
\hline
& University & 105 & 33.5 & 68 & 44.4 \\
\hline
& Postgraduate & 13 & 4.2 & 4 & 2.6 \\
\hline
& Prefer not to answer & 10 & 3.2 & 2 & 1.3 \\
\hline
& None of the above & 4 & 1.3 & 2 & 1.3 \\
\hline
Marital status & Single & 107 & 34.2 & 81 & 52.9 \\
\hline
& Married & 196 & 62.6 & 57 & 37.3 \\
\hline
& Divorced & 10 & 3.2 & 12 & 7.8 \\
\hline
& Widowed & 0 & 0.0 & 3 & 2.0 \\
\hline
Employment status & Paid or self-employed & 163 & 52.1 & 62 & 40.5 \\
\hline
& Retired & 12 & 3.8 & 1 & 0.7 \\
\hline
& Looking after home or family & 41 & 13.1 & 23 & 15.0 \\
\hline
& Unable sickness or disability & 0 & 0.0 & 0 & 0.0 \\
\hline
& Unemployed & 10 & 3.2 & 17 & 11.1 \\
\hline
& Unpaid or voluntary & 3 & 1.0 & 0 & 0.0 \\
\hline
& Student & 22 & 7.0 & 22 & 14.4 \\
\hline
& Prefer not to answer & 33 & 10.5 & 16 & 10.5 \\
\hline
& None of the above & 29 & 9.3 & 12 & 7.8 \\
\hline
\end{tabular}}
\end{table}
|
PMC5755402_table_4
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Phage name} & \textbf{GenBank accession no.} & \textbf{Isolation source} & \textbf{Location} & \textbf{Genome length (bp)} & \textbf{GC content (\%)} \\
\hline
BN12 & MG727695 & Bee debris & Cedar City, Utah, USA & 39,485 & 42.6 \\
\hline
Dragolir & MG727697 & Bee debris & Wisconsin, USA & 41,131 & 44 \\
\hline
Kiel007 & MG727696 & Bee debris & Salt Lake City, Utah, USA & 37,985 & 41.8 \\
\hline
Leyra & MG727701 & Bee debris & Idaho, USA & 42,276 & 41.4 \\
\hline
Likha & MG727702 & Honeycomb & American Fork, Utah, USA & 39,778 & 41.3 \\
\hline
Pagassa & MG727699 & P. larvae lysogen & Provo, Utah, USA & 40,035 & 42 \\
\hline
PBL1c & MG727698 & P. larvae lysogen & Iowa City, Iowa, USA & 40,611 & 41.2 \\
\hline
Tadhana & MG727700 & P. larvae lysogen & Provo, Utah, USA & 37,880 & 42.1 \\
\hline
\end{tabular}}
\end{table}
|
PMC6003738_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Compd} & \textbf{R1} & \textbf{R2} & \textbf{R3} & \textbf{TryR IC50 [mm]} \\
\hline
39 & Me & Me & 4’-Methylphenyl & 8.6 \\
\hline
40 & Me & CH2CH3 & Thiophen-2-yl & 12.8 \\
\hline
41 & Me & CH2CH3 & 2’-Fluoro-5’-Bromophenyl & 10.2 \\
\hline
42 & Me & H & 2’-Fluoro-5’-Bromophenyl & $>$100 \\
\hline
43 & H & H & 2’-Fluoro-5’-Bromophenyl & 92 \\
\hline
44 & Me & CH2CH3 & Pyridine-3-yl & $>$100 \\
\hline
45 & Me & CH2CH3 & 4’-Bromothiophen-2-yl & 13.0 \\
\hline
46 & Me & CH2CH3 & 4’-Trifluoromethylphenyl & 15.2 \\
\hline
47 & Me & CH2CH3 & Phenyl & 11.3 \\
\hline
48 & Me & CH2CH2NMe2 & 2’-Fluoro-5’-Bromophenyl & $>$100 \\
\hline
49 & Me & CH2CH3 & CH=CHC6H5 & 2.6 \\
\hline
50 & Me & CH(CH3)2 & 2’-Fluoro-5’-Bromophenyl & $>$50 \\
\hline
51 & Me & (CH2)3CH3 & 2’-Fluoro-5’-Bromophenyl & $>$100 \\
\hline
52 & Me & cyclopentyl & 2’-Fluoro-5’-Bromophenyl & $>$100 \\
\hline
\end{tabular}}
\end{table}
|
PMC2855869_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
& & \textbf{Total study population (n = 5655)} & \textbf{All ILI cases (n = 708)} & \textbf{ILI cases during influenza A(H3N2) outbreak period (n = 282)} & \textbf{Influenza A(H3N2) positive cases (n = 79)} & \textbf{Household transmission index cases (n = 43)} & \textbf{Household transmission secondary cases (n = 51)} \\
\hline
Gender & Male & 2814 (49.8\%) & 346 (48.9\%) & 138 (48.9\%) & 39 (49.4\%) & 19 (44.2\%) & 25(49.0\%) \\
\hline
& Female & 2841 (50.2\%) & 362 (51.1\%) & 144 (51.1\%) & 40 (50.6\%) & 24 (55.8\%) & 26 (51.0\%) \\
\hline
& Total & 5655 (100\%) & 708 (100\%) & 282 (100\%) & 79 (100\%) & 43 (100\%) & 51 (100\%) \\
\hline
Age & ,1 y & 146 (2.6\%) & 67 (9.5\%) & 18 (6.4\%) & 2 (2.5\%) & 2 (4.7\%) & 5 (9.8\%) \\
\hline
& 1–4 y & 510 (9.0\%) & 252 (35.6\%) & 104 (36.9\%) & 27 (34.2\%) & 20 (46.5\%) & 12 (23.5\%) \\
\hline
& 5–9 y & 444 (7.9\%) & 93 (13.1\%) & 48 (17.0\%) & 16 (20.3\%) & 6 (14.0\%) & 14 (27.5\%) \\
\hline
& 10–14 y & 502 (8.9\%) & 92 (13.0\%) & 36 (12.8\%) & 11 (13.9\%) & 5 (11.6\%) & 6 (11.8\%) \\
\hline
& 15–19 y & 573 (10.1\%) & 43 (6.1\%) & 12 (4.3\%) & 2 (2.5\%) & 1 (2.3\%) & 3 (5.9\%) \\
\hline
& 20–29 y & 1094 (19.3\%) & 39 (5.5\%) & 21 (7.4\%) & 6 (7.6\%) & 4 (9.3\%) & 6 (11.8\%) \\
\hline
& 30–39 y & 821 (14.5\%) & 36 (5.1\%) & 9 (3.2\%) & 5 (6.3\%) & 3 (7.0\%) & 1 (2.0\%) \\
\hline
& 40–49 y & 740 (13.1\%) & 34 (4.8\%) & 16 (5.7\%) & 5 (6.3\%) & 2 (4.7\%) & 3 (5.9\%) \\
\hline
& 50–64 y & 567 (10.0\%) & 32 (4.5\%) & 9 (3.2\%) & 3 (3.8\%) & 0 (0\%) & 1 (2.0\%) \\
\hline
& \$65 y & 258 (4.6\%) & 20 (2.8\%) & 9 (3.2\%) & 2 (2.5\%) & 0 (0\%) & 0 (0\%) \\
\hline
& Total & 5655 (100\%) & 708 (100\%) & 282 (100\%) & 79 (100\%) & 43 (100\%) & 51 (100\%) \\
\hline
& Mean age 6 SD (years) & 27.90619.12 & 14.09618.35 & 13.72617.62 & 14.96617.29 & 10.58612.86 & 12.27613.65 \\
\hline
& Median age (years) & 25 & 6 & 6 & 7 & 4 & 7 \\
\hline
& Range (years) & 0–94 & 0–94 & 0–80 & 0–70 & 0–47 & 0–62 \\
\hline
\end{tabular}}
\end{table}
|
PMC3302789_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \multicolumn{2}{|l|}{\textbf{Ascl1}} & \multicolumn{2}{|l|}{\textbf{Neurog1}} & \multicolumn{2}{|l|}{\textbf{Neurog2}} \\
\hline
& \textbf{Chick} & \textbf{Mouse} & \textbf{Chick} & \textbf{Mouse} & \textbf{Chick} & \textbf{Mouse} \\
\hline
nmesV & $\checkmark$ & $\checkmark$ & $\checkmark$ & $\checkmark$ & $\checkmark$ \\
\hline
nMLF & & & $\checkmark$ & $\checkmark$ & $\checkmark$ & $\checkmark$ \\
\hline
nMTT & & & $\checkmark$ & $\checkmark$ & $\checkmark$ & $\checkmark$ \\
\hline
nTPC & $\checkmark$ & $\checkmark$ \\
\hline
nTPOC & $\checkmark$ & $\checkmark$ \\
\hline
nIII & & & $\checkmark$ & $\checkmark$ & $\checkmark$ & $\checkmark$ \\
\hline
nIV & $\checkmark$ & $\checkmark$ & $\checkmark$ \\
\hline
\end{tabular}}
\end{table}
|
PMC5142277_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|}
\hline
& & \multicolumn{7}{|l|}{\textbf{Two-point LOD score of Family A and B ($\theta$)}} \\
\hline
\textbf{STR marker} & \textbf{Genetic position (cM)} & \textbf{0.00} & \textbf{0.01} & \textbf{0.05} & \textbf{0.10} & \textbf{0.20} & \textbf{0.30} & \textbf{0.40} & \textbf{Max LOD score ($\theta$)} \\
\hline
D2S2298 & 65.94 & -3.10 & -1.55 & -0.49 & -0.13 & 0.06 & 0.05 & 0.01 & 0.07 (0.24) \\
\hline
D2S391 & 70.31 & -12.55 & -7.66 & -4.08 & -2.45 & -1.08 & -0.55 & -0.29 & -0.03 (0.49) \\
\hline
D2S2739 & 73.61 & -7.48 & -4.65 & -1.96 & -0.84 & -0.11 & 0.01 & -0.04 & 0.01 (0.29) \\
\hline
D2S123 & 73.61 & -8.97 & -6.18 & -3.39 & -2.12 & -1.05 & -0.56 & -0.26 & -0.02 (0.49) \\
\hline
D2S2369 & 73.61 & -3.67 & -2.78 & -1.46 & -0.86 & -0.37 & -0.19 & -0.08 & -0.01 (0.49) \\
\hline
D2S2352 & 76.34 & -4.50 & -2.68 & -1.27 & -0.71 & -0.33 & -0.21 & -0.13 & -0.02 (0.49) \\
\hline
D2S2153 & 76.88 & -4.11 & -1.47 & 0.25 & 0.81 & 0.89 & 0.56 & 0.18 & 0.94 (0.16) \\
\hline
D2S378 & 77.43 & -4.33 & -2.37 & -0.87 & -0.278 & 0.09 & 0.12 & 0.06 & 0.13 (0.27) \\
\hline
D2S2279 & 77.97 & 1.04 & 1.00 & 0.82 & 0.62 & 0.31 & 0.11 & 0.01 & 1.04 (0.00) \\
\hline
D2S393 & 80.16 & -3.67 & -1.80 & -0.40 & 0.10 & 0.33 & 0.27 & 0.13 & 0.33 (0.21) \\
\hline
D2S357 & 80.16 & -4.28 & -2.04 & -0.32 & 0.26 & 0.45 & 0.29 & 0.07 & 0.46 (0.18) \\
\hline
D2S2332 & 80.69 & -0.34 & 1.57 & 1.93 & 1.83 & 1.83 & 0.81 & 0.33 & 1.93 (0.05) \\
\hline
D2S2206 & 81.49 & -5.26 & -2.75 & -0.58 & 0.24 & 0.59 & 0.44 & 0.17 & 0.59 (0.20) \\
\hline
D2S2320 & 82.29 & -3.56 & -1.85 & -0.53 & -0.09 & 0.05 & -0.06 & -0.13 & 0.05 (0.18) \\
\hline
D2S2397 & 82.82 & 0.60 & 0.59 & 0.55 & 0.49 & 0.36 & 0.22 & 0.10 & 0.60 (0.00) \\
\hline
D2S2231 & 84.42 & -5.76 & -4.20 & -1.71 & -0.58 & 0.14 & 0.22 & 0.12 & 0.22 (0.27) \\
\hline
& & \multicolumn{7}{|l|}{Two-point LOD score of Family A ($\theta$)} \\
\hline
STR marker & Genetic position (cM) & 0.00 & 0.01 & 0.05 & 0.10 & 0.20 & 0.30 & 0.40 & LODmax score ($\theta$) \\
\hline
D2S2298 & 65.94 & 0.15 & 0.14 & 0.10 & 0.06 & 0.01 & 0.00 & 0.000 & 0.15 (0.00) \\
\hline
D2S391 & 70.31 & -5.70 & -3.37 & -1.77 & -1.03 & -0.41 & -0.15 & -0.04 & -0.00 (0.49) \\
\hline
D2S2739 & 73.61 & -1.74 & -1.17 & -0.38 & -0.08 & 0.07 & 0.06 & 0.03 & 0.07 (0.23) \\
\hline
D2S123 & 73.61 & -2.27 & -1.70 & -0.87 & -0.51 & -0.23 & -0.11 & -0.03 & -0.00 (0.49) \\
\hline
D2S2369 & 73.61 & -2.44 & -1.84 & -0.94 & -0.53 & -0.19 & -0.06 & -0.01 & 0.00 (0.49) \\
\hline
D2S2352 & 76.34 & 0.57 & 0.55 & 0.46 & 0.36 & 0.20 & 0.08 & 0.02 & 0.57 (0.00) \\
\hline
D2S2153 & 76.88 & -1.76 & -1.20 & -0.39 & -0.08 & 0.08 & 0.07 & 0.03 & 0.09 (0.23) \\
\hline
D2S378 & 77.43 & -2.68 & -2.03 & -1.08 & -0.63 & -0.24 & -0.09 & -0.02 & 0.00 (0.49) \\
\hline
D2S2279 & 77.97 & 0.20 & 0.18 & 0.10 & 0.02 & -0.06 & -0.06 & -0.03 & 0.20 (0.00) \\
\hline
D2S393 & 80.16 & -2.30 & -1.71 & -0.85 & -0.46 & -0.16 & -0.04 & -0.00 & 0.00 (0.46) \\
\hline
D2S357 & 80.16 & -2.37 & -1.80 & -0.98 & -0.62 & -0.33 & -0.17 & -0.05 & -0.00 (0.49) \\
\hline
D2S2332 & 80.69 & 0.88 & 0.85 & 0.73 & 0.59 & 0.35 & 0.17 & 0.06 & 0.88 (0.00) \\
\hline
D2S2206 & 81.49 & -1.78 & -1.22 & -0.42 & -0.11 & 0.05 & 0.05 & 0.03 & 0.05 (0.25) \\
\hline
D2S2320 & 84.29 & 1.06 & 1.03 & 0.89 & 0.72 & 0.43 & 0.21 & 0.07 & 1.06 (0.00) \\
\hline
D2S2397 & 82.82 & 0.23 & 0.23 & 0.22 & 0.19 & 0.13 & 0.07 & 0.02 & 0.23 (0.00) \\
\hline
D2S2231 & 84.42 & -1.37 & -0.81 & -0.06 & 0.20 & 0.26 & 0.16 & 0.07 & 0.27 (0.16) \\
\hline
& & \multicolumn{7}{|l|}{Two-point LOD score of Family B ($\theta$)} \\
\hline
STR marker & Genetic position (cM) & 0.00 & 0.01 & 0.05 & 0.10 & 0.20 & 0.30 & 0.40 & LODmax score ($\theta$) \\
\hline
D2S2298 & 65.94 & -3.25 & -1.69 & -0.60 & -0.19 & 0.04 & 0.05 & 0.01 & 0.06 (0.25) \\
\hline
D2S391 & 70.31 & -6.85 & -4.29 & -2.31 & -1.41 & -0.67 & -0.40 & -0.25 & -0.03 (0.49) \\
\hline
D2S2739 & 73.61 & -5.74 & -3.48 & -1.58 & -0.76 & -0.18 & -0.05 & -0.07 & -0.02 (0.49) \\
\hline
D2S123 & 73.61 & -6.70 & -4.48 & -2.52 & -1.61 & -0.82 & -0.45 & -0.22 & -0.02 (0.49) \\
\hline
D2S2369 & 73.61 & -1.23 & -0.94 & -0.52 & -0.33 & -0.19 & -0.13 & -0.07 & -0.01 (0.49) \\
\hline
D2S2352 & 76.34 & -5.08 & -3.25 & -1.75 & -1.08 & -0.54 & -0.29 & -0.16 & -0.02 (0.49) \\
\hline
D2S2153 & 76.88 & -2.35 & -0.28 & 0.64 & 0.89 & 0.81 & 0.49 & 0.15 & 0.91 (0.13) \\
\hline
D2S378 & 77.43 & -1.65 & -0.34 & 0.21 & 0.35 & 0.33 & 0.20 & 0.08 & 0.37 (0.13) \\
\hline
D2S2279 & 77.97 & 0.84 & 0.82 & 0.72 & 0.60 & 0.37 & 0.17 & 0.04 & 0.84 (0.00) \\
\hline
D2S393 & 80.16 & -1.36 & -0.09 & 0.45 & 0.56 & 0.49 & 0.32 & 0.14 & 0.56 (0.12) \\
\hline
D2S357 & 80.16 & -1.91 & -0.25 & 0.65 & 0.88 & 0.78 & 0.46 & 0.13 & 0.90 (0.12) \\
\hline
D2S2332 & 80.69 & -1.22 & 0.72 & 1.20 & 1.24 & 1.00 & 0.64 & 0.27 & 1.25 (0.08) \\
\hline
D2S2206 & 81.49 & -3.47 & -1.54 & -0.15 & 0.35 & 0.54 & 0.39 & 0.14 & 0.55 (0.19) \\
\hline
D2S2320 & 84.29 & -4.62 & -2.87 & -1.42 & -0.82 & -0.39 & -0.27 & -0.20 & -0.03 (0.49) \\
\hline
D2S2397 & 82.82 & 0.37 & 0.36 & 0.34 & 0.30 & 0.23 & 0.16 & 0.08 & 0.37 (0.00) \\
\hline
D2S2231 & 84.42 & -4.40 & -3.39 & -1.66 & -0.78 & -0.12 & 0.05 & 0.05 & 0.06 (0.34) \\
\hline
\end{tabular}}
\end{table}
|
PMC3413431_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\multicolumn{2}{|l|}{\textbf{Braconids}} & \multicolumn{4}{|l|}{\textbf{Allelic association flies//braconids}} \\
\hline
\textbf{species} & \textbf{samples} & \textbf{N} & \textbf{\%} & \textbf{alleles} & \textbf{Anastrepha host} \\
\hline
D. areolatus & 8 & 1 & 0.125 & wsp-156 & macrura \\
\hline
D. fluminensis & 2 & 2 & 1.000 & wsp-156 & montei; pickeli \\
\hline
O. bellus & 4 & 1 & 0.250 & wsp-23 & obliqua \\
\hline
U. anastrephae & 6 & 6 & 1.000 & wsp-23 & amita; fraterculus-1 fraterculus 2; obliqua \\
\hline
\end{tabular}}
\end{table}
|
PMC5127160_table_3
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Variables} & \multicolumn{2}{|l|}{\textbf{PMTR (n = 6626)}} & \multicolumn{2}{|l|}{\textbf{PTR (n = 18749)}} & \multicolumn{2}{|l|}{\textbf{No resection (n = 13216)}} \\
\hline
& \textbf{n} & \textbf{\%} & \textbf{n} & \textbf{\%} & \textbf{n} & \textbf{\%} \\
\hline
\multicolumn{7}{|l|}{Age} \\
\hline
$<$ = 70 years old & 4974 & 75.1 & 12784 & 68.2 & 8966 & 67.8 \\
\hline
$>$ 70 years old & 1652 & 24.9 & 5965 & 31.8 & 4250 & 32.2 \\
\hline
\multicolumn{7}{|l|}{Gender} \\
\hline
Female & 3527 & 53.2 & 8585 & 45.8 & 5622 & 42.5 \\
\hline
Male & 3099 & 46.8 & 10164 & 54.2 & 7594 & 57.5 \\
\hline
\multicolumn{7}{|l|}{Marital status} \\
\hline
Married & 3813 & 57.5 & 10332 & 55.1 & 6309 & 47.7 \\
\hline
Single/Divorced/Separated/Widowed & 2585 & 39.0 & 7787 & 41.5 & 6277 & 47.5 \\
\hline
Unknown & 228 & 3.5 & 630 & 3.4 & 630 & 4.8 \\
\hline
\multicolumn{7}{|l|}{Primary tumor site} \\
\hline
RCRC & 2778 & 41.9 & 8433 & 45.0 & 3971 & 30.0 \\
\hline
LCRC & 3848 & 58.1 & 10316 & 55.0 & 9245 & 70.0 \\
\hline
\multicolumn{7}{|l|}{Grade} \\
\hline
Well-differentiated & 239 & 3.6 & 756 & 4.0 & 593 & 4.5 \\
\hline
Moderate-differentiated & 4196 & 63.3 & 11709 & 62.5 & 6062 & 45.9 \\
\hline
Poor-differentiated & 1651 & 24.9 & 5004 & 26.7 & 1922 & 14.5 \\
\hline
Undifferentiated & 247 & 3.7 & 527 & 2.8 & 107 & 0.8 \\
\hline
Unknown & 293 & 4.4 & 753 & 4.0 & 4532 & 34.3 \\
\hline
\multicolumn{7}{|l|}{CEA} \\
\hline
Positive/outside reference range & 3588 & 54.2 & 9974 & 53.2 & 8332 & 63.0 \\
\hline
Negative/within reference range & 1105 & 16.7 & 2684 & 14.3 & 1032 & 7.8 \\
\hline
Unknown & 1933 & 29.2 & 6091 & 32.5 & 3852 & 29.1 \\
\hline
\multicolumn{7}{|l|}{T-stage*} \\
\hline
T1 & 103 & 1.6 & 403 & 2.1 & 2469 & 18.7 \\
\hline
T2 & 178 & 2.7 & 541 & 2.9 & 178 & 1.3 \\
\hline
T3 & 3694 & 55.8 & 11105 & 59.2 & 1864 & 14.1 \\
\hline
T4 & 2532 & 38.2 & 6367 & 34.0 & 2108 & 16.0 \\
\hline
Tx & 119 & 1.8 & 333 & 1.8 & 6597 & 49.9 \\
\hline
\multicolumn{7}{|l|}{N-stage*} \\
\hline
0 & 1180 & 17.8 & 3412 & 18.2 & 5457 & 41.3 \\
\hline
1 & 2354 & 35.5 & 6169 & 32.9 & 3259 & 24.7 \\
\hline
2 & 3003 & 45.3 & 8884 & 47.4 & 487 & 3.7 \\
\hline
Nx & 89 & 1.3 & 284 & 1.5 & 4013 & 30.4 \\
\hline
\multicolumn{7}{|l|}{Liver metastasis} \\
\hline
Positive & 1781 & 26.9 & 4810 & 25.7 & 4880 & 36.9 \\
\hline
Negative & 793 & 12.0 & 1809 & 9.6 & 1200 & 9.1 \\
\hline
Unknown & 4052 & 61.2 & 12130 & 64.7 & 7136 & 54.0 \\
\hline
\multicolumn{7}{|l|}{Lung metastasis} \\
\hline
Positive & 280 & 4.2 & 1246 & 6.6 & 2149 & 16.3 \\
\hline
Negative & 2271 & 34.3 & 5287 & 28.2 & 3785 & 28.6 \\
\hline
Unknown & 4075 & 61.5 & 12216 & 65.2 & 7282 & 55.1 \\
\hline
\multicolumn{7}{|l|}{Brain metastasis} \\
\hline
Positive & 31 & 0.5 & 50 & 0.3 & 81 & 0.6 \\
\hline
Negative & 2506 & 37.8 & 6462 & 34.5 & 5827 & 44.1 \\
\hline
Unknown & 4089 & 61.7 & 12237 & 65.3 & 7308 & 55.3 \\
\hline
\end{tabular}}
\end{table}
|
PMC5668074_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Compound (µg/ml)} & \textbf{IL-8 released (pg/ml)} \\
\hline
Medium alone & 24.6 $\pm$ 1.5 \\
\hline
Tryptase 2.0 & 105.2 $\pm$ 5.3* \\
\hline
Elastase 0.3 & 108.4 $\pm$ 13.2* \\
\hline
Benzamidine 30 & 37.6 $\pm$ 4.4 \\
\hline
Leupeptine 30 & 27.4 $\pm$ 5.6 \\
\hline
MSACK 30 & 22.1 $\pm$ 4.3 \\
\hline
Tryptase 2.0 + Benzamidine 30 & 66.9 $\pm$ 4.8† \\
\hline
Tryptase 2.0 + Leupeptin 30 & 100 $\pm$ 1.7 \\
\hline
Elastase 0.3 + MSACK 30 & 26.9 $\pm$ 3.6† \\
\hline
\end{tabular}}
\end{table}
|
PMC1489934_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \textbf{U11} & \textbf{U22} & \textbf{U33} & \textbf{U12} & \textbf{U13} & \textbf{U23} \\
\hline
O1 & 0.0818 (13) & 0.0494 (10) & 0.0792 (12) & −0.0028 (9) & −0.0243 (10) & 0.0088 (8) \\
\hline
O2 & 0.0772 (13) & 0.0656 (11) & 0.0607 (10) & 0.0033 (10) & −0.0179 (10) & −0.0049 (8) \\
\hline
O3 & 0.1079 (16) & 0.0447 (10) & 0.0717 (12) & −0.0132 (10) & −0.0130 (10) & −0.0080 (8) \\
\hline
O4 & 0.1079 (16) & 0.0432 (10) & 0.0804 (13) & 0.0016 (10) & −0.0083 (11) & 0.0055 (8) \\
\hline
N1 & 0.0563 (13) & 0.0572 (12) & 0.0505 (11) & −0.0060 (10) & −0.0044 (10) & −0.0047 (10) \\
\hline
N2 & 0.0592 (13) & 0.0466 (10) & 0.0524 (12) & −0.0060 (10) & −0.0057 (10) & −0.0047 (9) \\
\hline
C1 & 0.0540 (15) & 0.0509 (14) & 0.0454 (13) & −0.0051 (12) & 0.0009 (12) & −0.0036 (11) \\
\hline
C2 & 0.0554 (16) & 0.0456 (13) & 0.0512 (13) & −0.0011 (12) & 0.0017 (12) & 0.0048 (11) \\
\hline
C3 & 0.0545 (15) & 0.0468 (13) & 0.0568 (15) & −0.0027 (12) & −0.0045 (12) & −0.0056 (11) \\
\hline
C4 & 0.0558 (15) & 0.0541 (14) & 0.0447 (13) & 0.0000 (12) & −0.0014 (12) & −0.0044 (11) \\
\hline
C5 & 0.0660 (17) & 0.0483 (13) & 0.0591 (15) & 0.0080 (13) & −0.0030 (13) & 0.0046 (11) \\
\hline
C6 & 0.0646 (17) & 0.0449 (13) & 0.0616 (16) & −0.0051 (12) & 0.0000 (14) & −0.0026 (11) \\
\hline
C7 & 0.086 (2) & 0.0762 (19) & 0.0699 (18) & −0.0058 (17) & −0.0192 (15) & −0.0202 (15) \\
\hline
C8 & 0.0521 (15) & 0.0521 (14) & 0.0556 (14) & −0.0075 (12) & 0.0005 (12) & −0.0052 (12) \\
\hline
C9 & 0.0694 (17) & 0.0417 (13) & 0.0470 (13) & −0.0014 (12) & 0.0046 (12) & −0.0046 (11) \\
\hline
C10 & 0.0573 (15) & 0.0429 (12) & 0.0445 (13) & 0.0017 (11) & 0.0012 (11) & −0.0044 (10) \\
\hline
C11 & 0.0699 (18) & 0.0465 (14) & 0.0518 (14) & 0.0044 (13) & 0.0070 (13) & −0.0021 (11) \\
\hline
C12 & 0.0727 (19) & 0.0635 (16) & 0.0515 (15) & 0.0114 (15) & −0.0028 (13) & 0.0005 (13) \\
\hline
C13 & 0.078 (2) & 0.0724 (18) & 0.0620 (17) & 0.0062 (16) & −0.0158 (15) & −0.0129 (14) \\
\hline
C14 & 0.086 (2) & 0.0499 (14) & 0.0707 (18) & −0.0079 (14) & −0.0158 (16) & −0.0095 (13) \\
\hline
C15 & 0.0698 (18) & 0.0456 (13) & 0.0601 (15) & 0.0024 (13) & −0.0052 (13) & −0.0020 (11) \\
\hline
C16 & 0.112 (3) & 0.092 (2) & 0.0700 (19) & 0.034 (2) & −0.0149 (17) & 0.0079 (16) \\
\hline
O5 & 0.1172 (17) & 0.0435 (9) & 0.0748 (12) & 0.0068 (10) & −0.0079 (11) & 0.0063 (8) \\
\hline
\end{tabular}}
\end{table}
|
PMC2979542_table_3
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Phase} & \textbf{Transcriptional Factors} & \textbf{CDC28/cyclins/CDC genes} & \textbf{Modules containing these factors (ID)} \\
\hline
G1 & SWI4, MBP1, STB1, SWI6, ACE2, SKN7 & CLN3, FUS3, FAR1, CDC36, CDC39, CLN2, CDC37, CDC28, CLN1 & 0, 1, 14, 30, 32, 42, 44, 66, 79 \\
\hline
S & SWI4, MBP1, NDD1, SWI6, SKN7 & CDC24, CDC7, CDC8, CDC21 & 0, 12, 14, 30, 66, 77 \\
\hline
G2 & FKH1, FKH2, NDD1, MCM1 & CDC11, CLB2, CDC15, CLB4, CDC28, CDC3, CDC5, CDC14, CLB1, CLB3 & 1, 3, 14, 30, 32, 42, 44, 79 \\
\hline
M & MCM1, SWI5, ACE2 & CDC28, CLB1, CLB2, CLB3, CLB4 & 0, 1, 3, 14, 30, 32, 42, 44, 79, \\
\hline
\end{tabular}}
\end{table}
|
PMC3143111_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
& \textbf{WT (n = 8)} & \textbf{PTRF−/− (n = 6)} \\
\hline
BW (g) & 24.0$\pm$0.6 & 19.7$\pm$0.3** \\
\hline
HW (mg) & 123.7$\pm$5.4 & 107.1$\pm$3.1* \\
\hline
TL (mm) & 16.9$\pm$0.2 & 15.6$\pm$0.1** \\
\hline
HW/BW (mg/g) & 5.15$\pm$0.17 & 5.44$\pm$0.16 \\
\hline
HW/TL (mg/mm) & 7.32$\pm$0.33 & 6.88$\pm$0.19 \\
\hline
LW (mg) & 142.1$\pm$9.9 & 162.4$\pm$4.4 \\
\hline
LW/BW (mg/g) & 5.96$\pm$0.46 & 8.24$\pm$0.13** \\
\hline
LW/TL (mg/mm) & 8.38$\pm$0.53 & 10.43$\pm$0.26** \\
\hline
\end{tabular}}
\end{table}
|
PMC5017623_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\multicolumn{2}{|l|}{\textbf{Starting a LC-SRC—Do’s and Don’ts}} \\
\hline
\textbf{Do} & \textbf{Don’t} \\
\hline
+ Involve students from different college years and faculty (physicians) +Let students organize the LC-SRC and let them carry the responsibility & - Immediately start an extensive program with many students and doctors. Start a small pilot with only enthusiastic participants and evaluate \\
\hline
+ Try to create additional value for other healthcare workers, patients, and the organization & - Compete for patients with other healthcare workers such as registrars \\
\hline
+ Involve patients (e.g., giving students feedback) & - Underestimate the abilities of motivated students to cope with difficult cases or situations, however provide adequate coaching and supervision \\
\hline
\end{tabular}}
\end{table}
|
PMC4613888_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\multicolumn{2}{|l|}{\textbf{Incidence and Severity of Treatment-Related AEs by Preferred Term}} & \multicolumn{2}{|l|}{\textbf{Tat 7.5 mg (N = 41)}} & \multicolumn{3}{|l|}{\textbf{Severityc}} & \multicolumn{2}{|l|}{\textbf{Tat 30 mg (N = 46)}} & \multicolumn{3}{|l|}{\textbf{Severityc}} \\
\hline
\textbf{System Organ Class (SOC)} & \textbf{MedDRA Preferred Term} & \textbf{na} & \textbf{n/Nb (\%)} & \textbf{1} & \textbf{2} & \textbf{3} & \textbf{na} & \textbf{n/Nb (\%)} & \textbf{1} & \textbf{2} & \textbf{3} \\
\hline
Blood and lymphatic system disorders & Lymphocytic infiltration & 1 & 2.4 & 1 & 0 & 0 & 0 & 0.0 & 0 & 0 & 0 \\
\hline
Cardiac disorders & Chest Discomfort & 1 & 2.4 & 0 & 0 & 1 & 0 & 0.0 & 0 & 0 & 0 \\
\hline
& Bradycardia & 1 & 2.4 & 0 & 1 & 0 & 0 & 0.0 & 0 & 0 & 0 \\
\hline
Eye disorders & Photophobia & 1 & 2.4 & 1 & 0 & 0 & 0 & 0.0 & 0 & 0 & 0 \\
\hline
& Visual impairment & 1 & 2.4 & 1 & 0 & 0 & 0 & 0.0 & 0 & 0 & 0 \\
\hline
& Conjunctivitis & 1 & 2.4 & 1 & 0 & 0 & 0 & 0.0 & 0 & 0 & 0 \\
\hline
Gastrointestinal disorders & Nausea & 0 & 0.0 & 0 & 0 & 0 & 1 & 2.2 & 1 & 0 & 0 \\
\hline
General disorders & Asthenia & 1 & 2.4 & 1 & 0 & 0 & 1 & 2.2 & 1 & 0 & 0 \\
\hline
& Fatigue & 1 & 2.4 & 1 & 0 & 0 & 0 & 0.0 & 0 & 0 & 0 \\
\hline
& Hyperidrosis & 1 & 2.4 & 1 & 0 & 0 & 0 & 0.0 & 0 & 0 & 0 \\
\hline
& Injection site discomfort & 0 & 0.0 & 0 & 0 & 0 & 1 & 2.2 & 1 & 0 & 0 \\
\hline
& Injection site erythema & 0 & 0.0 & 0 & 0 & 0 & 1 & 2.2 & 1 & 0 & 0 \\
\hline
& Injection Site Irritation & 4 & 9.8 & 4 & 0 & 0 & 2 & 4.3 & 2 & 0 & 0 \\
\hline
& Injection Site Pain & 10 & 24.4 & 10 & 0 & 0 & 13 & 28.3 & 13 & 0 & 0 \\
\hline
& Malaise & 1 & 2.4 & 1 & 0 & 0 & 0 & 0.0 & 0 & 0 & 0 \\
\hline
& Pyrexia & 0 & 0.0 & 0 & 0 & 0 & 4 & 8.7 & 4 & 0 & 0 \\
\hline
Musculoskeletal and connective tissue disorders & Muscular weakness & 0 & 0.0 & 0 & 0 & 0 & 1 & 2.2 & 1 & 0 & 0 \\
\hline
Nervous System Disorders & Agitation & 1 & 2.4 & 1 & 0 & 0 & 0 & 0.0 & 0 & 0 & 0 \\
\hline
& Aphasia & 1 & 2.4 & 0 & 0 & 1 & 0 & 0.0 & 0 & 0 & 0 \\
\hline
& Disturbance in attention & 1 & 2.4 & 1 & 0 & 0 & 0 & 0.0 & 0 & 0 & 0 \\
\hline
& Dysarthria & 1 & 2.4 & 0 & 0 & 1 & 0 & 0.0 & 0 & 0 & 0 \\
\hline
& Headache & 3 & 7.3 & 3 & 0 & 0 & 1 & 2.2 & 1 & 0 & 0 \\
\hline
& Paraesthesia oral & 1 & 2.4 & 0 & 0 & 1 & 0 & 0.0 & 0 & 0 & 0 \\
\hline
& Trigeminal neuralgia & 1 & 2.4 & 0 & 1 & 0 & 0 & 0.0 & 0 & 0 & 0 \\
\hline
Skin and subcutaneous tissue disorders & Erythema & 0 & 0.0 & 0 & 0 & 0 & 1 & 2.2 & 1 & 0 & 0 \\
\hline
& Pruritus generalised & 1 & 2.4 & 1 & 0 & 0 & 0 & 0.0 & 0 & 0 & 0 \\
\hline
\end{tabular}}
\end{table}
|
PMC2978690_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
D—H···A & D—H & H···A & D···A & D—H···A \\
\hline
C3—H3···O1i & 0.93 & 2.95 & 3.687 (6) & 138 \\
\hline
C1—H1···O1ii & 0.98 & 2.47 & 3.266 (5) & 139 \\
\hline
C1—H1···O2ii & 0.98 & 3.48 & 4.331 (6) & 147 \\
\hline
C4—H4···O2iii & 0.93 & 2.54 & 3.371 (5) & 148 \\
\hline
C5—H5···F1iv & 0.93 & 2.81 & 3.640 (5) & 150 \\
\hline
C8—H8B···O2v & 0.97 & 2.50 & 3.406 (5) & 156 \\
\hline
\end{tabular}}
\end{table}
|
PMC4647347_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{AAA model} & \textbf{P (mmHg)} & \textbf{dAAA,max (cm)} & \textbf{Thickness t (cm)} & \textbf{$\alpha$} & \textbf{$\beta$} & \textbf{Stress (Authors' results) (MPa)} & \multicolumn{2}{|l|}{\textbf{Modified Laplace Equation}} & \multicolumn{2}{|l|}{\textbf{Original Laplace Equation}} \\
\hline
& & & & & & & \textbf{Stress (MPa)} & \textbf{Error} & \textbf{Stress (MPa)} & \textbf{Error} \\
\hline
Fillinger [3,4] & 120 & 6.7 & 0.19 & 0 & 0.4 & 0.32 & 0.34 & 6.3\% & 0.28 & 13\% \\
\hline
& 130 & 5.5 & 0.19 & 0 & 0.4 & 0.30 & 0.28 & 6.7\% & 0.25 & 16.7\% \\
\hline
Wang [29] & 128 & 6.1 & 0.184 & 0.54 & 0.33 & 0.19 & 0.208 & 9.5\% & 0.28 & 47\% \\
\hline
& 155 & 6.4 & 0.175 & 0.29 & 0.9 & 0.35 & 0.34 & 2.9\% & 0.38 & 8.6\% \\
\hline
Vorp [36] & 120 & 6.0 & 0.15 & 0 & 0.3 & 0.33 & 0.34 & 3\% & 0.31 & 6\% \\
\hline
Raghavan [45] & 115 & 5.2 & 0.19 & 0 & 0.65 & 0.23 & 0.21 & 8.7\% & 0.2 & 13\% \\
\hline
& 188 & 5.5 & 0.19 & 0 & 0.9 & 0.43 & 0.46 & 6.9\% & 0.36 & 16\% \\
\hline
Thubrikar [15] & 120 & 5.86 & 0.104 & 0 & 0.5 & 0.37 & 0.39 & 5.4\% & 0.45 & 22\% \\
\hline
& 120 & 5.86 & 0.158 & 0 & 0.5 & 0.3 & 0.299 & 0.3\% & 0.29 & 3.3\% \\
\hline
Li [44] & 120 & 5.0 & 0.05 & 0.15 & 1 & 0.43 & 0.41 & 4.6\% & 0.80 & 85.6\% \\
\hline
\end{tabular}}
\end{table}
|
PMC1421417_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{Healthy Individuals} & \multicolumn{2}{|l|}{\textbf{Sepsis Patients}} & \textbf{P value*} \\
\hline
& & \textbf{Normal Response to UK} & \textbf{Low Response to UK} \\
\hline
Coagulation Parameters & (N = 10) & (N = 22) & (N = 18) \\
\hline
PT ratio & 1.06 (1.01–1.10) & 1.26 (1.12–1.42)^ & 1.46 (1.28–1.62)$\S$$\S$ & $<$0.001 \\
\hline
aPTT ratio & 1.04 (0.98–1.07) & 1.08 (1.01–1.26) & 1.17 (1.07–1.31) & 0.05 \\
\hline
Fibrinogen (mg/dl) & 252 (244–283) & 565 (384–682)^^ & 529 (370–749)$\S$$\S$ & $<$0.001 \\
\hline
D-dimer (ng/ml) & 78 (60–127) & 1467 (810–6170)^^ & 2250 (1182–3472)$\S$$\S$ & $<$0.001 \\
\hline
PAI-1 antigen (ng/ml) & 3.3 (1.5–5.1) & 36.1 (20–39.6)^^ & 30.7 (24.3–43.9)$\S$$\S$ & $<$0.001 \\
\hline
PAI-1 activity (ng/ml) & 0.2 (0.1–0.3) & 4.0 (0.6–5.7)^ & 3.8 (1.6–19.0)$\S$$\S$ & $<$0.001 \\
\hline
TAFI (\%) & 110 (93–124) & 104 (83–130) & 111 (91–133) & 0.94 \\
\hline
TEG Parameters & (N = 40) & (N = 22) & (N = 18) \\
\hline
TEG_r (min) & 9.1 (7.6–10.1) & 7.5 (6.1–10.5) & 11.0 (7.2–14.2) ° & 0.03 \\
\hline
TEG_angle (deg) & 55.9 (47.6–62.6) & 59.6 (48.8–68.6) & 51.3 (39.6–59.9) & 0.16 \\
\hline
TEG_MA (mm) & 61.0 (57.3–65.4) & 70.8 (66.5–77.0) ^^ & 66.9 (52.6–73.2) ° & $<$0.001 \\
\hline
TEG_Ly30 (\%) & 1.2 (0.1–2.7) & 0.3 (0–1.4) & 0.1 (0–0.9) $\S$ & 0.02 \\
\hline
\multicolumn{5}{|l|}{UK-TEG} \\
\hline
UK-TEG_r (min) & 8 (7.0–8.7) & 7.6 (5.8–10.0) & 11.3 (6.6–12.6) & 0.06 \\
\hline
UK-TEG_angle (deg) & 54.7 (37.5–65.0) & 49.4 (34.3–67.0) & 42.3 (32.8–57.3) & 0.40 \\
\hline
UK-TEG_MA (mm) & 25.2 (15.6–39.8) & 22.3 (9.4–29.0) & 53.3 (49.0–68.4) $\S$$\S$ °° & $<$0.001 \\
\hline
UK-TEG_Ly30 (\%) & 91.3 (88.5–93.1) & 88.5 (76.7–92.4) & 22.9 (0–50.2) $\S$$\S$ °° & $<$0.001 \\
\hline
\end{tabular}}
\end{table}
|
PMC4550424_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{the Primer/Probe name} & \textbf{Sequence 5′ – 3′} \\
\hline
EP5-8-F & ACGCGCGACCAGCTGCTAACCGTG \\
\hline
P1007ATG-R & TCGCAGCACGGCGCCCTCCCCAT \\
\hline
Ex1end-F & GTCGCTGCCCAAGAATGCAG \\
\hline
and EP3-13-R & TCCGCCCGAAGGTAGTTGATCC \\
\hline
control 10908-F & GTCCTGTCCATTTCGCTTTG \\
\hline
11202 R & CGGCGTGTGTTTATATATGG \\
\hline
each U6 probe & TCATCCTTGCGCAGGGGCCA \\
\hline
used: smRNA-P1 probe4 R & GCGTGGCGTCGACGTGGAACCGAGCTCGGC \\
\hline
smRNA-P1 probe5 R & TGCAGTTTTGGACCCTTTGCTCGGCGCCATAGGCTAT \\
\hline
and smRNA-P1 probe6 R & CCTCTCACCGTCCGCAGTGTCAACGTTAAG GCGGGGGAAATCATTAGGGAGGGCCGGC \\
\hline
tested Thioredoxin-like F & GGACCAGAAGATTGCAGAAG \\
\hline
2008; Thioredoxin-like R & CAGCATAGACAGGAGCAATG \\
\hline
each EP3-13 & TGGAGGTCGCTGCCCAAGAAT \\
\hline
three P1-L010 & TCCGCCCGAAGGTAGTTGATCC \\
\hline
STRS1-F & CAGGTGCTTGACATCTTGGA \\
\hline
STRS1-R & AGCTTCCCGTCTTTCTCCTC \\
\hline
JAC1-F & CCTGCTCTAAAACCGACGAC \\
\hline
JAC1-R & GCCTTCCCATTCTGTTGATG \\
\hline
WHP-F & GACCCGACCTACGAATAATG \\
\hline
isolated WHP-R & AACTTGAGCTGGTGCACTG \\
\hline
UV- MATE-F & CTCTGCCTCGAGACCTGGTA \\
\hline
RNA MATE-R & GACAGAGAGTGAGGCCAAGG \\
\hline
cDNA LAC10-F & GGTAGCCGTTTTCATCGTAGAG \\
\hline
LAC10-R & AGGCCTCCTTTGTTAGATCCAC \\
\hline
PCR F2H-F & CGGTCCATCCAAATTCAG \\
\hline
using F2H-R & ACCAACATCGAACGGGTA \\
\hline
RHM-F & ACTTTACTTTTGGGCTGTCG \\
\hline
Primers RHM-R & TCGACCTCCTCTGCTGTTC \\
\hline
using CCR-F & CTCCTGCTCCTGTCCTACCAG \\
\hline
Three CCR-R & CCTCCTCTCACCTTGTTCAG \\
\hline
control PAL1-F & GTCTCGACTCTCCACACCAC \\
\hline
data, PAL1-R & GGAGAGAACCAGCAGCAGTG \\
\hline
used; PAL2-F & GCCTCAGTGCCTCACCTAAG \\
\hline
are PAL2-R & GGGCGAGGCGGTTATATAGG \\
\hline
min PAL3-F & GGCTGCCATCCTATCCTATCC \\
\hline
for PAL3-R & CCACCACTCACCTTGCTACAG \\
\hline
Melting UGT1-F & GAGGAGCAGATTCGGTGAGC \\
\hline
UGT1-R & CGACTGACGACAGTGTCTGG \\
\hline
98◦C). UGT3-F & ACTGGGCCTAGGCTAGACTGC \\
\hline
that UGT3-R & GACCACCACAGTGGGGTATG \\
\hline
final UGT4-F & AGTACGGCCATCCTCTGGTC \\
\hline
UGT4-R & CACCTTGACTCCGACCTTCC \\
\hline
UGT5-F & TGATTTCTGCGAGCCTGT \\
\hline
UGT5-R & AAGAAACGAGTGCGTGGA \\
\hline
\end{tabular}}
\end{table}
|
PMC4838615_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
& \multicolumn{13}{|l|}{\textbf{Case}} \\
\hline
& \textbf{1} & \textbf{3} & \textbf{4} & \textbf{5} & \textbf{6} & \textbf{7} & \textbf{8} & \textbf{9} & \textbf{10} & \textbf{11} & \textbf{12} & \textbf{13} & \textbf{14} \\
\hline
Glomerular mesangial expansion (0–3) & 1 & 1 & 0 & 1 & 1 & 1 & 1 & 1 & 2 & 1 & 1 & 1 & 1 \\
\hline
Glomerular hypertrophy (0 or 1) & 1 & 1 & 0 & 0 & 0 & 1 & 0 & 1 & 1 & 1 & 0 & 0 & 0 \\
\hline
Global sclerosis (\%) & 23.7 & 14.3 & 5.6 & 6.3 & 0 & 18.2 & 30.0 & 0 & 28.6 & 14.3 & 0 & 0 & 4.0 \\
\hline
Polar vasculosis (0 or 1) & 0 & 0 & 0 & 0 & 1 & 0 & 1 & 0 & 1 & 0 & 0 & 0 & 0 \\
\hline
Arteriosclerosis (0–2) & 0 & 0 & 1 & 1 & 0 & 0 & 0 & 0 & 2 & 0 & 0 & 0 & 0 \\
\hline
Arteriolar hyalinosis (0–3) & 1 & 0 & 0 & 0 & 1 & 1 & 1 & 0 & 1 & 2 & 0 & 0 & 1 \\
\hline
Interstitial fibrosis and tubular atrophy (\%) & 5 & 5 & 5 & 5 & 0 & 20 & 30 & 5 & 10 & 10 & 5 & 5 & 5 \\
\hline
\end{tabular}}
\end{table}
|
PMC5956044_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Maternal 25(OH)D} & \textbf{Bacteria} & \textbf{\&n} & \textbf{Unadjusted B (95\% CI)} & \textbf{\#Adjusted B (95\% CI)} \\
\hline
Quintile 1 & Bifidobacterium spp. & 176 & 0 (reference) & 0 (reference) \\
\hline
Quintile 2 & & 178 & 0.06 (-0.12, 0.25) & -0.02 (-0.20, 0.16) \\
\hline
Quintile 3 & & 175 & 0.07 (-0.11, 0.26) & -0.01 (-0.20, 0.17) \\
\hline
Quintile 4 & & 175 & -0.09 (-0.27, 0.10) & -0.14 (-0.33, 0.06) \\
\hline
Quintile 5 & & 176 & -0.19 (-0.38, -0.01) & -0.25 (-0.46, -0.05) \\
\hline
p for linear trend & & & & p = 0.010* \\
\hline
Quintile 1 & Escherichia coli & 155 & 0 (reference) & 0 (reference) \\
\hline
Quintile 2 & & 160 & -0.06 (-0.34, 0.22) & -0.09 (-0.35, 0.17) \\
\hline
Quintile 3 & & 160 & 0.04 (-0.24, 0.32) & -0.04 (-0.31, 0.22) \\
\hline
Quintile 4 & & 156 & -0.06 (-0.34, 0.22) & -0.06 (-0.33, 0.22) \\
\hline
Quintile 5 & & 159 & -0.04 (-0.32, 0.24) & -0.09 (-0.38, 0.19) \\
\hline
p for linear trend & & & & p = 0.655 \\
\hline
Quintile 1 & Bacteroides fragilis group & 138 & 0 (reference) & 0 (reference) \\
\hline
Quintile 2 & & 159 & 0.15 (-0.15, 0.45) & 0.06 (-0.19, 0.30) \\
\hline
Quintile 3 & & 150 & 0.42 (0.12, 0.72) & 0.30 (0.05, 0.55) \\
\hline
Quintile 4 & & 139 & 0.29 (-0.02, 0.60) & 0.24 (-0.02, 0.50) \\
\hline
Quintile 5 & & 142 & 0.09 (-0.22, 0.39) & 0.28 (0.01, 0.55) \\
\hline
P for linear trend & & & & p = 0.014* \\
\hline
Quintile 1 & Clostridium difficile & 46 & 0 (reference) & 0 (reference) \\
\hline
Quintile 2 & & 42 & -0.40 (-1.22, 0.43) & -0.34 (-1.16, 0.48) \\
\hline
Quintile 3 & & 55 & -0.43 (-1.20, 0.34) & -0.40 (-1.19, 0.40) \\
\hline
Quintile 4 & & 42 & -0.04 (-0.86, 0.79) & 0.19 (-0.66, 1.04) \\
\hline
Quintile 5 & & 41 & -0.61 (-1.45, 0.22) & -0.30 (-1.18. 0.58) \\
\hline
P for linear trend & & & & p = 0.949 \\
\hline
Quintile 1 & Lactobacillus spp. & 60 & 0 (reference) & 0 (reference) \\
\hline
Quintile 2 & & 68 & 0.01 (-0.21, 0.24) & 0.01 (-0.21, 0.22) \\
\hline
Quintile 3 & & 49 & -0.11 (-0.35, 0.14) & -0.18 (-0.41, 0.06) \\
\hline
Quintile 4 & & 51 & 0.02 (-0.22, 0.26) & 0.04 (-0.20, 0.28) \\
\hline
Quintile 5 & & 58 & -0.06 (-0.30, 0.17) & 0.08 (-0.17, 0.33) \\
\hline
P for linear trend & & & & p = 0.459 \\
\hline
\end{tabular}}
\end{table}
|
PMC5679631_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Characteristics} & \textbf{Negative remodeling n = 50} & \textbf{Intermediate remodeling n = 95} & \textbf{Positive remodeling n = 153} & \textbf{P-value} \\
\hline
\\
\hline
Age (years) & 62.18 $\pm$ 10.25 & 63.38 $\pm$ 10.57 & 62.18 $\pm$ 11.73 & 0.688 \\
\hline
Male & 40 (66.7) & 81 (65.3) & 131 (70.8) & 0.716 \\
\hline
Waist Circumference (cm) & 88.5 $\pm$ 7.3 & 89.5 $\pm$ 6.6 & 90.3 $\pm$ 9.5 & 0.576 \\
\hline
BMI (Kg/m2) & 24.8 $\pm$ 2.7 & 24.3 $\pm$ 2.8 & 25.1 $\pm$ 3.3 & 0.106 \\
\hline
Total cholesterol (mg/dL) & 178.0 $\pm$ 48.2 & 176.9 $\pm$ 43.5 & 180.5 $\pm$ 47.9 & 0.825 \\
\hline
Triglycerides (mg/dL) & 138.0 $\pm$ 82.4 & 145.1 $\pm$ 93.6 & 146.2 $\pm$ 91.6 & 0.854 \\
\hline
HDL-C (mg/dL) & 43.3 $\pm$ 10.3 & 42.5 $\pm$ 10.0 & 41.5 $\pm$ 10.3 & 0.528 \\
\hline
LDL-C (mg/dL) & 100.6 $\pm$ 38.8 & 104.3 $\pm$ 37.4 & 107.8 $\pm$ 40.8 & 0.504 \\
\hline
HbA1C (\%) & 6.56 $\pm$ 1.54 & 6.39 $\pm$ 1.09 & 6.67 $\pm$ 1.39 & 0.309 \\
\hline
hsCRP (mg/dl) & 0.16 $\pm$ 0.27 & 0.51 $\pm$ 1.02 & 0.67 $\pm$ 1.41 & 0.045 \\
\hline
HOMA-IR & 2.38 $\pm$ 1.80 & 2.75 $\pm$ 2.26 & 3.55 $\pm$ 3.59 & 0.045 \\
\hline
MetS Score & 1.78 $\pm$ 0.97 & 2.16 $\pm$ 1.14 & 2.23 $\pm$ 1.17 & 0.051 \\
\hline
\end{tabular}}
\end{table}
|
PMC4472609_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
& \multicolumn{4}{|l|}{\textbf{C26:0LPC/C22:0 LPCa}} & \multicolumn{4}{|l|}{\textbf{\%C26:0LPCa}} \\
\hline
\textbf{Cell type} & \textbf{Mean control} & \textbf{Mean patient} & \textbf{FCb} & \textbf{Pc} & \textbf{Mean control} & \textbf{Mean patient} & \textbf{FCb} & \textbf{Pc} \\
\hline
Fibroblastd & 1.24 & 16.44 & 13.3 & $<$3$\times$10−4 & 0.82 & 10.33 & 12.6 & $<$9$\times$10−6 \\
\hline
Fibroblaste & 0.70 & 13.96 & 19.8 & $<$7$\times$10−3 & 0.23 & 3.36 & 14.3 & 0.01 \\
\hline
iPSCf & 6.61 & 1.31 & −5.0 & 0.001 & 0.36 & 0.11 & −3.4 & 0.07 \\
\hline
NPCg & 7.12 & 8.25 & 1.2 & 0.8 & 1.68 & 1.60 & −1.1 & 0.9 \\
\hline
\end{tabular}}
\end{table}
|
PMC4553005_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Species} & \textbf{Common Name} & \textbf{Crop/Native} & \textbf{Family} & \textbf{CC Scorea} \\
\hline
Asclepias syriaca L. & Common milkweed & Native & Asclepiadaceae & 0 \\
\hline
Desmodium canadense (L.) DC. & Showy ticktrefoil & Native & Fabaceae & 5 \\
\hline
Panicum virgatum L. & Switchgrass & Native & Poaceae & 6 \\
\hline
Raphanus sativus L. var. Sparkler & Radish & Crop & Brassicaceae & N/A \\
\hline
Solanum lycopersicum L. var. Beefsteak & Tomato & Crop & Solanaceae & N/A \\
\hline
\end{tabular}}
\end{table}
|
PMC4468158_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
\textbf{Patient ID} & \textbf{Gender} & \textbf{Age} & \textbf{UPDRS (motor)} & \textbf{Duration of disease} & \textbf{GDS} & \textbf{MMSE} & \textbf{Medication (mg/day)} \\
\hline
1 & F & 49 & 17 & 8 & 1 & 30 & Levodopa (150), benserazide (37.5), orphenadrine (50) \\
\hline
2 & F & 77 & 5 & 8 & 0 & 26 & Levodopa (100), benserazide (28.5), lisuride (0.2), orphenadrine (50) \\
\hline
3 & M & 72 & 8 & 7 & 2 & 30 & Levodopa (400), carbidopa (100), benztropine (1) \\
\hline
4 & F & 62 & 44 & 12 & 1 & 29 & Levodopa (96), benserazide (24), ropinirole (8) \\
\hline
5 & F & 59 & 18 & 3 & 2 & 29 & Levodopa (700), carbidopa (175) \\
\hline
6 & F & 66 & 49 & 9 & 2 & 28 & Levodopa (400), carbidopa (100) \\
\hline
7 & F & 68 & 11 & 2 & 2 & 28 & Levodopa (800), carbidopa (200), ropinirole (4.5) \\
\hline
8 & M & 69 & 42 & 9 & 4 & 29 & Levodopa (1950), carbidopa (487.5), entacapone (600) \\
\hline
PD Mean (SD) & 2M and 7F & 65.25 (8.65) & 24.25 (17.81) & 7.25 (3.28) & 1.75 (1.17) & 28.63 (1.30) \\
\hline
AMC Mean (SD) & 2M and 7F & 64.88 (9.25) & - & - & 1.13 (1.46) & 29.63 (0.52) \\
\hline
\end{tabular}}
\end{table}
|
PMC4997014_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{QTL} & \textbf{Chra} & \textbf{Posb} & \textbf{Rangeb} & \textbf{Peak markerc} & \textbf{No. Seg. Fam.d} & \textbf{PBON-HOLM e} & \textbf{pG f} & \textbf{CV Freq.g} & \textbf{Effecth} & \textbf{CGi} \\
\hline
QFt.HEB25-1b & 1H & 128.3 & 128.0-128.3 & SCRI_RS_150786 & 25 & 2.41E-18 & 0.01 & 68 & −1.4 & HvELF3 [46,47] \\
\hline
QFt.HEB25-2b & 2H & 23.0 & 16.8-23.8 & BK_16 & 24 & 3.39E-130 & 0.36 & 100 & −9.5 & Ppd-H1 [15] \\
\hline
QFt.HEB25-2c & 2H & 57.4 & 56.4-58.1 & BOPA2_12_30265 & 25 & 2.25E-42 & 0.05 & 84 & −3.0 & HvCEN [35] \\
\hline
QFt.HEB25-3c & 3H & 108.4 & 107.8-109.2 & BOPA1_ABC07496_ pHv1343_02 & 23 & 2.62E-62 & 0.04 & 83 & −3.1 & denso [45] \\
\hline
QFt.HEB25-4a & 4H & 3.5 & 3.5 & BOPA2_12_31458 & 24 & 5.08E-15 & 0.05 & 82 & 3.2 \\
\hline
QFt.HEB25-4e & 4H & 113.4 & 113.4-114.3 & SCRI_RS_216897 & 24 & 4.58E-17 & 0.02 & 100 & 2.2 & Vrn-H2 [17] \\
\hline
QFt.HEB25-5d & 5H & 125.5 & 125.5-125.8 & BOPA1_4795_782 & 24 & 2.31E-33 & 0.06 & 60 & 3.8 & Vrn-H1 [18] \\
\hline
QFt.HEB25-7a & 7H & 34.3 & 25.9-34.3 & BOPA2_12_30895 & 23 & 6.04E-69 & 0.07 & 100 & 4.1 & Vrn-H3 [16] \\
\hline
\end{tabular}}
\end{table}
|
PMC4426605_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Depth} & \textbf{Bottom duration} & \textbf{Breathing gas} & \textbf{Water temperature(◦C)} & \textbf{\# of divers} & \textbf{Age} & \textbf{Weight (kg)} \\
\hline
33 ft. (10.05 m) & 30 min & Air & 14.96 $\pm$ 0.82 & 11 & 42.53 $\pm$ 2.17 & 83.50 $\pm$ 3.16 \\
\hline
66 ft. (20.1 m) & 30 min & Air & 12.78 $\pm$ 0.57 & 11 & 41.13 $\pm$ 2.03 & 83.28 $\pm$ 2.85 \\
\hline
99 ft. (30.17 m) & 15 min & Air & 14.74 $\pm$ 0.69 & 13 & 42.31 $\pm$ 2.57 & 85.17 $\pm$ 3.31 \\
\hline
99 ft. (30.17 m) & 15 min & Nitrox & 14.49 $\pm$ 0.77 & 14 & 41.92 $\pm$ 2.41 & 84.43 $\pm$ 3.15 \\
\hline
150 ft. (45.72 m) & 15 min & Trimix & 12.73 $\pm$ 0.43 & 12 & 43.08 $\pm$ 1.83 & 89.77 $\pm$ 2.19 \\
\hline
200 ft. (60.96 m) & 10 min & Trimix & 9.75 $\pm$ 0.36 & 10 & 40.60 $\pm$ 2.40 & 90.54 $\pm$ 2.21 \\
\hline
\end{tabular}}
\end{table}
|
PMC5835073_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|}
\hline
& \textbf{Age} & \textbf{Click} & \textbf{0.5 kHz} & \textbf{1 kHz} & \textbf{2 kHz} & \textbf{4 kHz} & \textbf{8 kHz} & \textbf{12 kHz} & \textbf{16 kHz} \\
\hline
Age & 1.00 \\
\hline
Click & 0.79* & 1.00 \\
\hline
0.5 kHz & 0.89** & 0.76* & 1.00 \\
\hline
1 kHz & 0.84** & 0.71* & 0.91** & 1.00 \\
\hline
2 kHz & 0.87** & 0.57 & 0.79* & 0.90** & 1.00 \\
\hline
4 kHz & 0.84** & 0.75* & 0.90** & 0.91** & 0.75* & 1.00 \\
\hline
8 kHz & 0.83** & 0.96** & 0.82** & 0.85** & 0.70* & 0.84** & 1.00 \\
\hline
12 kHz & 0.74** & 0.67* & 0.8 & 0.93** & 0.78* & 0.87** & 0.80* & 1.00 \\
\hline
16 kHz & 0.69* & 0.59 & 0.86** & 0.89** & 0.71* & 0.83** & 0.67* & 0.89** & 1.00 \\
\hline
\end{tabular}}
\end{table}
|
PMC3563598_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|}
\hline
& \textbf{Mask} & \textbf{L} & & & \textbf{R} & & & \textbf{Mask} & \textbf{Condition} \\
\hline
Incongruent-green group & Condition & Cong-gr & Incong-bl & Incong-gr & Cong-gr & Incong-bl & Incong-gr \\
\hline
& Mean & 2.17 & 2.75 & 2.5 & 1.87 & 2.43 & 2.48 & F (1, 10) = 0.57 & F (2, 20) = 4.53 \\
\hline
& SD & (0.67) & (0.69) & (0.72) & (0.55) & (1.27) & (1.14) & n.s. & p = .0238 \\
\hline
Congruent-blue group & Condition & Cong-gr & Incong-bl & Cong-bl & Cong-gr & Incong-bl & Cong-bl \\
\hline
& Mean & 3.50 & 4.28 & 3.48 & 2.70 & 3.16 & 2.49 & F (1, 9) = 9.24 & F (2, 18) = 6.77 \\
\hline
& SD & (1.95) & (2.99) & (1.92) & (1.23) & (1.75) & (1.29) & p = .0140 & p = .006 \\
\hline
\end{tabular}}
\end{table}
|
PMC3341400_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Respondent characteristics} & \textbf{Guideline compliance scorea} & \textbf{p Value} \\
\hline
Specialty & \multicolumn{2}{|l|}{Anaesthesiology (n = 81) 7.9 $\pm$ 1.9 Emergency medicine (n = 31) 6.4 $\pm$ 2.7 Intensive care (n = 81) 7.1 $\pm$ 2.7 Surgery (n = 46) 6.4 $\pm$ 3.2} & 0.004 \\
\hline
\\
\hline
\\
\hline
\\
\hline
ICU type & \multicolumn{2}{|l|}{Exclusively trauma (n = 10) 8.6 $\pm$ 2.0 Mixed surgical-medical (n = 172) 6.9 $\pm$ 2.7 Surgical/neurosurgical (n = 61) 7.7 $\pm$ 2.3} & 0.03 \\
\hline
\\
\hline
\\
\hline
Hospital type & \multicolumn{2}{|l|}{University (n = 55) 7.1 $\pm$ 2.6 Nonuniversity (n = 188) 7.2 $\pm$ 2.7} & 0.80 \\
\hline
\\
\hline
Trauma centre & \multicolumn{2}{|l|}{Trauma centre (n = 180) 7.4 $\pm$ 2.5 Nontrauma centre (n = 63) 6.6 $\pm$ 2.8} & 0.016 \\
\hline
\\
\hline
Trauma leader & \multicolumn{2}{|l|}{Anaesthesiologist (n = 71) 7.6 $\pm$ 1.8 Emergency medicine (n = 53) 6.6 $\pm$ 2.7 Intensivist (n = 50) 7.0 $\pm$ 2.8 Surgeon (n = 104) 7.5 $\pm$ 2.7} & 0.12 \\
\hline
\\
\hline
\\
\hline
\\
\hline
ICU beds & \multicolumn{2}{|l|}{$<$15 beds (n = 130) 7.2 $\pm$ 2.4 $\geq$15 beds (n = 111) 7.2 $\pm$ 2.4} & 0.96 \\
\hline
\\
\hline
\end{tabular}}
\end{table}
|
PMC4672560_table_3
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\multicolumn{2}{|l|}{\textbf{Variables}} & \textbf{Number of patients} & \textbf{Percentage (\%)} \\
\hline
\textbf{Gender} & \textbf{Male} & \textbf{261865} & \textbf{69.71} \\
\hline
& Female & 113764 & 30.29 \\
\hline
Age & 18- & 112863 & 30.05 \\
\hline
& 30- & 129606 & 34.50 \\
\hline
& 40- & 69453 & 18.49 \\
\hline
& 50- & 33685 & 8.97 \\
\hline
& 60- & 30022 & 7.99 \\
\hline
Marital Status & Married & 203353 & 54.14 \\
\hline
& Never married & 92033 & 24.50 \\
\hline
& Widowed or divorced & 69985 & 18.63 \\
\hline
& Unknown & 10258 & 2.73 \\
\hline
Nationality & Han & 276910 & 73.72 \\
\hline
& Uygur/Zhuang/Yi/Dai & 69649 & 18.54 \\
\hline
& Others & 23773 & 6.33 \\
\hline
& Unknown & 5297 & 1.41 \\
\hline
Occupation & Farmer & 184742 & 49.18 \\
\hline
& Housekeeping, housework and unemployed & 64471 & 17.16 \\
\hline
& Worker & 21306 & 5.67 \\
\hline
& Business & 15817 & 4.21 \\
\hline
& Migrant workers & 11013 & 2.93 \\
\hline
& Government staff & 9636 & 2.57 \\
\hline
& Retired & 8291 & 2.21 \\
\hline
& Others or unknown & 60353 & 16.07 \\
\hline
Education & Illiteracy & 33533 & 8.93 \\
\hline
& Elementary & 118204 & 31.47 \\
\hline
& Junior high school & 149217 & 39.72 \\
\hline
& Senior high school & 42099 & 11.21 \\
\hline
& College or above & 25389 & 6.76 \\
\hline
& Unknown & 7187 & 1.91 \\
\hline
Disease status when identified & HIV & 190135 & 50.62 \\
\hline
& AIDS & 185494 & 49.38 \\
\hline
Possible transmission route & Heterosexual & 189766 & 50.52 \\
\hline
& IDU & 83972 & 22.36 \\
\hline
& Blood sell & 39354 & 10.48 \\
\hline
& Homosexual & 32958 & 8.77 \\
\hline
& Blood transfusion & 11244 & 2.99 \\
\hline
& Sexual + IDU & 4662 & 1.24 \\
\hline
& Others or unknown & 13673 & 3.64 \\
\hline
Treatment & No & 196119 & 52.21 \\
\hline
& Yes & 179510 & 47.79 \\
\hline
\end{tabular}}
\end{table}
|
PMC4914945_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{Unique reads} & \textbf{Percent (\%)} & \textbf{Clean reads} & \textbf{Percent (\%)} \\
\hline
Total small RNAs & 3017665 & 100\% & 11243850 & 100\% \\
\hline
Mapping to genome & 153264 & 5.08\% & 4925432 & 43.81\% \\
\hline
\end{tabular}}
\end{table}
|
PMC4872230_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \textbf{WD-sHCC (n = 31)} & \textbf{HGDN (n = 21)} & \textbf{Sensitivity} & \textbf{Specificity} & \textbf{PPV} & \textbf{NPV} \\
\hline
LIFR negative & 18 & 2 & 58.10\% & 90.50\% & 59.40\% & 90.00\% \\
\hline
CD34 positive & 30 & 8 & 96.80\% & 61.90\% & 78.90\% & 92.90\% \\
\hline
Predicted by LIFR + CD34 & 29 & 19 & 93.50\% & 90.50\% & 93.50\% & 90.50\% \\
\hline
\end{tabular}}
\end{table}
|
PMC4466664_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{General practices} \\
\hline
Number of GP practices & 54 \\
\hline
Number of clusters & 40 \\
\hline
Number of included patients per participating cluster, range & 11-79 \\
\hline
\multicolumn{2}{|l|}{of Type of practice,\%} \\
\hline
year, Single-handed practice & 44 \\
\hline
by One or more partner practice & 41 \\
\hline
Healthcare centre & 15 \\
\hline
Practice location,\% urban & 72 \\
\hline
Patient practice population, n (range) & 3418 (1750-16907) \\
\hline
the Ethnic minorities,\% & 15 \\
\hline
\multicolumn{2}{|l|}{General practitioners} \\
\hline
size the Number of participating GP’s & 76 \\
\hline
sam- Gender GP,\% male & 61 \\
\hline
(n-1)$\rho$, Age GP, years (range) & 50 (35-62) \\
\hline
Years practicing, years (SD) & 16 (8.2) \\
\hline
\end{tabular}}
\end{table}
|
PMC3637448_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \multicolumn{2}{|l|}{\textbf{2TCM full input}} & \multicolumn{2}{|l|}{\textbf{Logan full input}} & \multicolumn{2}{|l|}{\textbf{Logan PBIF}} \\
\hline
\textbf{Region} & \textbf{Retest Variability (\%)} & \textbf{ICC} & \textbf{Retest Variability (\%)} & \textbf{ICC} & \textbf{Retest Variability (\%)} & \textbf{ICC} \\
\hline
Prefrontal & 16 & 0.91 & 17 & 0.89 & 14 & 0.89 \\
\hline
Occipital & 13 & 0.90 & 15 & 0.90 & 17 & 0.89 \\
\hline
Hippocampus & 15 & 0.86 & 18 & 0.85 & 14 & 0.88 \\
\hline
Putamen & 17 & 0.88 & 18 & 0.87 & 17 & 0.86 \\
\hline
Thalamus & 15 & 0.89 & 17 & 0.87 & 17 & 0.90 \\
\hline
Cerebellum & 15 & 0.85 & 15 & 0.86 & 14 & 0.88 \\
\hline
Pons & 9 & 0.94 & 13 & 0.93 & 17 & 0.92 \\
\hline
White Matter & 11 & 0.88 & 16 & 0.87 & 17 & 0.89 \\
\hline
\end{tabular}}
\end{table}
|
PMC3618181_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
\textbf{Number of samples in TD} & \textbf{Kernel type} & \multicolumn{2}{|l|}{\textbf{SD_GraTrans_Opt_ SamSel+TD_train}} & \multicolumn{2}{|l|}{\textbf{SD_GraTrans_FG+TD_ train}} & \multicolumn{2}{|l|}{\textbf{TD_train}} \\
\hline
& & \textbf{FP (\%)} & \textbf{FDR (\%)} & \textbf{FP (\%)} & \textbf{FDR (\%)} & \textbf{FP (\%)} & \textbf{FDR (\%)} \\
\hline
60 & Linear & 10 & 13.04 & 16.67 & 26.32 & 20 & 22.22 \\
\hline
& RBF & 6.67 & 11.76 & 13.33 & 20 & 23.33 & 24.14 \\
\hline
40 & Linear & 15 & 20 & 45 & 47.37 & 20 & 23.53 \\
\hline
& RBF & 15 & 15.79 & 20 & 20 & 15 & 15 \\
\hline
20 & Linear & 10 & 11.11 & 10 & 11.11 & 10 & 11.11 \\
\hline
& RBF & 30 & 27.27 & 40 & 33.3 & 20 & 22.22 \\
\hline
\end{tabular}}
\end{table}
|
PMC5930507_table_6
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
D—H···A & D—H & H···A & D···A & D—H···A \\
\hline
C21A—H21A···O2Bi & 0.95 & 2.41 & 3.1270 (19) & 132 \\
\hline
C14B—H14B···O3Aii & 0.95 & 2.50 & 3.4345 (17) & 168 \\
\hline
C15B—H15B···O4Aiii & 0.95 & 2.62 & 3.4638 (17) & 148 \\
\hline
C22B—H22B···O2A & 0.95 & 2.54 & 3.2054 (17) & 127 \\
\hline
C14A—H14A···O3B & 0.95 & 2.44 & 3.2303 (16) & 140 \\
\hline
\end{tabular}}
\end{table}
|
PMC3414307_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Dose instilled as 10 consecutive inoculations (cfu/20ml)} & \textbf{No. of treated mice} & \textbf{Fertility outcome} \\
\hline
Control (PBS) & 3 & 3/3 (100\%) \\
\hline
104 & 3 & 0/3 (0\%) \\
\hline
106 & 3 & 0/3 (0\%) \\
\hline
108 & 3 & 0/3 (0\%) \\
\hline
\end{tabular}}
\end{table}
|
PMC3525590_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Name} & \textbf{Age} & \textbf{Profession} & \textbf{Lifestyle} & \textbf{Type of tracker} & \textbf{Tracking activities} & \textbf{Engagement level} \\
\hline
Joanna & 25–30 & Business development & Very active and attends the gym several times a week. Highly competitive and driven. Often participated in challenges via the activity tracker. Felt addicted to the tracker. Enjoys team sports. Family orientated. & Fitbit Charge Monitors: Heart rate, Automatic sleep tracking, Steps, Activities, Food and water logging, Distance, Stairs climbed, Caller ID & Used to track: Activities Steps & Used to be a Hyper-engaged user. The WAT needed resetting which has not been done. Has decided not to continue using it. \\
\hline
Christine & 25–30 & Business development & Very active and attends the gym several times a week. Highly competitive and driven. Often participated in challenges via the activity tracker. Was motivated to challenge others. Felt addicted to the tracker. & Fitbit Charge Monitors: Heart rate, Automatic sleep tracking, Steps, Activities, Food and water logging, Distance, Stairs climbed, Caller ID & Used to track: Steps Sleep Activities & Used to be a Hyper-engaged user. Currently, the WAT is broken and not in use. \\
\hline
Mary & 30–35 & Human Resources & Very active and attends the gym several times a week. Wants to stay in control and has reduced the number of activities tracked. Wants to be healthy rather than calorie-focused. Does not use the activity tracker app. Accesses data via the tracker itself. & Fitbit Alta Monitors: Automatic sleep tracking, Steps, Smart tracking of activities, Food and water logging, Distance, Move reminders & Steps & Engaged \\
\hline
Jane & 55–60 & Operations management & Recovering from surgery. Important to do a good number of steps each day. Walking and jazz dance help her to recover and move away from being incapacitated post-surgery. & Fitbit Flex Monitors: Manual sleep tracking, Steps, Activities, Food and water logging, Distance & Steps Water intake Activities & Engaged \\
\hline
Sofia & 35–40 & Training and development & Highly competitive and enjoys the outdoors. Equestrian at a competitive level. Attends the gym regularly. Walks the dog. More focus on physical activity than gym-based exercise. Always exceeding the targets set. & Jawbone UP Monitors: Heart rate, Automatic sleep tracking, Steps, Activities, Calories, Water intake, Distance & Activities Sleep Steps & Hyper-engaged \\
\hline
Catherine & 50–55 & Operations management & Very active. Family focused and community orientated. Attends the gym regularly. Is highly aware and interested in fitness and health. & Fitbit Charge Monitors: Heart rate, Automatic sleep tracking, Steps, Activities, Calories, Water intake, Distance, Stairs climbed, Caller ID & Heart rate Steps Sleep Competes against others in work & Engaged \\
\hline
Paula & 35–40 & Business development & Very active. Recently had knee surgery. Attends team sport. Attends the gym regularly and enjoys weight training. Partner is a personal trainer. Evaluates performance on a weekly basis. & Fitbit Charge Monitors: Heart rate, Automatic sleep tracking, Steps, Activities, Calories, Water intake, Distance, Stairs climbed, Caller ID & Training purposes, specific exercises rather than daily use, heart rate for intensity training Monitors almost everything & Hyper-engaged \\
\hline
Maria & 30–35 & Program coordinator & Active lifestyle. Often busy on the weekend. Important to always wear the tracker. Highly reliant on tracking sleep. Needs the data to verify daily activity. & Fitbit Charge Monitors: Heart rate, Automatic sleep tracking, Steps, Activities, Calories, Water intake, Distance, Stairs climbed, Caller ID & Sleep Heart rate Steps Activities & Engaged \\
\hline
\end{tabular}}
\end{table}
|
PMC6099722_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
& \textbf{Huh7} & \textbf{HepG2} & \textbf{SMMC-7721} & \textbf{PLC} & \textbf{MHCCLM3} & \textbf{MHCC97L} & \textbf{SK-Hep1} & \textbf{Hep3B} \\
\hline
AR $\alpha$1 & + & - & - & - & - & - & - & - \\
\hline
AR $\alpha$2 & ++++ & - & - & - & - & - & - & +++ \\
\hline
AR $\alpha$3 & + & + & +++ & +++ & + & + & + & - \\
\hline
AR $\alpha$4 & + & - & - & - & - & - & + & + \\
\hline
AR $\alpha$5 & - & - & - & - & - & - & - & - \\
\hline
AR $\alpha$6 & - & - & - & - & - & - & - & - \\
\hline
AR $\beta$1 & ++ & - & - & - & - & - & - & ++ \\
\hline
AR $\beta$2.1 & - & - & - & - & - & - & - & - \\
\hline
AR $\beta$2.2 & - & - & - & + & - & - & - & - \\
\hline
AR $\beta$3 & - & - & - & - & - & - & - & - \\
\hline
AR $\gamma$1 & - & - & - & - & - & - & - & - \\
\hline
AR $\gamma$2 & - & - & - & + & - & - & - & - \\
\hline
AR $\gamma$3 & - & - & - & + & - & - & - & - \\
\hline
AR $\epsilon$2 & + & + & ++ & - & ++ & ++ & - & - \\
\hline
AR $\delta$ & - & - & ++ & - & - & - & - & - \\
\hline
AR $\theta$ & - & + & - & - & - & + & + & - \\
\hline
AR $\pi$ & - & - & + & + & - & - & - & - \\
\hline
BR 1.1 & + & - & + & - & + & + & ++ & - \\
\hline
BR1.2 & ++ & ++ & +++ & ++ & ++ & ++ & +++ & ++ \\
\hline
BR1.3 & ++ & + & + & + & + & + & ++ & + \\
\hline
BR1.4 & ++ & + & ++ & + & ++ & ++ & +++ & ++ \\
\hline
BR 2 & - & - & - & - & - & - & + & - \\
\hline
\end{tabular}}
\end{table}
|
PMC3643652_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Harmonic order} & \multicolumn{3}{|l|}{\textbf{RCVT /V}} & \multicolumn{3}{|l|}{\textbf{CVT /V}} & \multicolumn{3}{|l|}{\textbf{VT/V}} \\
\hline
& \textbf{100\%+1} & \textbf{100\%+0.8} & \textbf{50\%+0.8} & \textbf{100\%+1} & \textbf{100\%+0.8} & \textbf{50\%+0.8} & \textbf{100\%+1} & \textbf{100\%+0.8} & \textbf{50\%+0.8} \\
\hline
2 & 7.7467 & 7.7679 & 7.8087 & 7.8050 & 7.8184 & 7.8758 & 7.6903 & 7.7729 & 7.8069 \\
\hline
3 & 12.132 & 12.128 & 12.167 & 12.368 & 12.315 & 12.409 & 12.0795 & 12.2107 & 12.1218 \\
\hline
4 & 22.796 & 22.527 & 23.073 & 23.832 & 23.439 & 24.191 & 22.6907 & 23.3205 & 23.0523 \\
\hline
5 & 8.8914 & 8.8871 & 8.8851 & 9.6356 & 9.5443 & 9.6651 & 8.8616 & 8.9121 & 8.8710 \\
\hline
6 & 4.4491 & 4.4531 & 4.4423 & 5.0469 & 4.9729 & 5.0710 & 4.4287 & 4.4387 & 4.4340 \\
\hline
7 & 2.7864 & 2.7899 & 2.7779 & 3.4175 & 3.3440 & 3.4512 & 2.7771 & 2.7821 & 2.7729 \\
\hline
8 & 1.9165 & 1.9190 & 1.9093 & 2.5683 & 2.4449 & 2.6333 & 1.9053 & 1.9097 & 1.9038 \\
\hline
9 & 1.4444 & 1.4498 & 1.4434 & 2.2121 & 2.0052 & 2.3606 & 1.4402 & 1.4398 & 1.4361 \\
\hline
10 & 1.1148 & 1.1169 & 1.1104 & 1.6170 & 1.3852 & 2.0170 & 1.1100 & 1.1103 & 1.1073 \\
\hline
11 & 0.8943 & 0.8959 & 0.8948 & 0.7072 & 0.5472 & 0.7491 & 0.8902 & 0.8931 & 0.8847 \\
\hline
12 & 0.7385 & 0.7400 & 0.7378 & 0.2020 & 0.1885 & 0.2339 & 0.7346 & 0.7370 & 0.7352 \\
\hline
13 & 0.6160 & 0.6171 & 0.6163 & 0.1261 & 0.1233 & 0.1409 & 0.6131 & 0.6148 & 0.6044 \\
\hline
14 & 0.5233 & 0.5241 & 0.5234 & 0.1637 & 0.1671 & 0.1675 & 0.5203 & 0.5219 & 0.5220 \\
\hline
15 & 0.4570 & 0.4576 & 0.4571 & 0.1749 & 0.1984 & 0.2004 & 0.4542 & 0.4556 & 0.4440 \\
\hline
\end{tabular}}
\end{table}
|
PMC6219776_table_5
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Indexes} & \textbf{$\lambda$} & \textbf{F} & \textbf{df1} & \textbf{df2} & \textbf{Sig.} \\
\hline
CA724 (U/mL) & 0.525 & 105.874 & 4 & 469 & $\leq$0.001 \\
\hline
CA242 (U/mL) & 0.551 & 192.145 & 2 & 471 & $\leq$0.001 \\
\hline
TT (s) & 0.511 & 74.545 & 6 & 467 & $\leq$0.001 \\
\hline
PLT (∗109/L) & 0.506 & 64.897 & 7 & 466 & $\leq$0.001 \\
\hline
CRP (mg/L) & 0.537 & 134.919 & 3 & 470 & $\leq$0.001 \\
\hline
AST (U/L) & 0.519 & 86.86 & 5 & 468 & $\leq$0.001 \\
\hline
Ascites & 0.587 & 331.467 & 1 & 472 & $\leq$0.001 \\
\hline
\end{tabular}}
\end{table}
|
PMC6008646_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|}
\hline
Question & Response & \multicolumn{2}{|l|}{AthSD} & \multicolumn{2}{|l|}{AthNoSD} & \multicolumn{2}{|l|}{Unanswered} & \multicolumn{2}{|l|}{Total} \\
\hline
& & N & \% & N & \% & N & \% & N & \% & Pearson X2 and p value \\
\hline
Do you eat breakfast before all competitions & Yes & 184 & 88.89 & 124 & 89.86 & 0 & 0.00 & 308 & 89.02 & 8.208 0.017 \\
\hline
& No & 23 & 11.11 & 14 & 10.14 & 1 & 100.00 & 38 & 10.98 \\
\hline
& Total & 207 & 100.00 & 138 & 100.00 & 1 & 100.00 & 346 & 100.00 \\
\hline
Question & Response & \multicolumn{2}{|l|}{Men} & \multicolumn{2}{|l|}{Women} & \multicolumn{2}{|l|}{Total} \\
\hline
& & N & \% & N & \% & N & \% & & & Pearson X2 and p value \\
\hline
How many days a week do you eat breakfast & 0 & 5 & 3.52 & 3 & 1.26 & 8 & 2.11 & & & 27.691 0.001 \\
\hline
& 1 & 1 & 0.70 & 5 & 2.10 & 6 & 1.58 \\
\hline
& 2 & 13 & 9.15 & 20 & 8.40 & 33 & 8.68 \\
\hline
& 3 & 20 & 14.08 & 11 & 4.62 & 31 & 8.16 \\
\hline
& 4 & 13 & 9.15 & 11 & 4.62 & 24 & 6.32 \\
\hline
& 5 & 28 & 19.72 & 29 & 12.18 & 57 & 15.00 \\
\hline
& 6 & 10 & 7.04 & 22 & 9.24 & 32 & 8.42 \\
\hline
& 7 & 52 & 36.62 & 137 & 57.56 & 189 & 49.74 \\
\hline
& Total & 142 & 100.00 & 238 & 100.00 & 380 & 100.00 \\
\hline
& & N & \% & N & \% & N & \% & & & Pearson X2 and p value \\
\hline
What time of day do you normally eat breakfast & I don’t eat breakfast & 7 & 4.93 & 6 & 2.51 & 13 & 3.41 & & & 28.418 0.001 \\
\hline
& 5:00–7:00 AM & 8 & 5.63 & 45 & 18.83 & 53 & 13.91 \\
\hline
& 7:00 AM–9:00 AM & 70 & 49.30 & 134 & 56.07 & 204 & 53.54 \\
\hline
& 9:00–11:00 AM & 56 & 39.44 & 47 & 19.67 & 103 & 27.03 \\
\hline
& 11:00 AM–1:00 PM & 1 & 0.70 & 7 & 2.93 & 8 & 2.10 \\
\hline
& Total & 142 & 100.00 & 239 & 100.00 & 381 & 100.00 \\
\hline
& & N & \% & N & \% & N & \% & & & Pearson X2 and p value \\
\hline
Do you eat breakfast before all practices & Yes & 79 & 55.24 & 158 & 65.83 & 237 & 61.88 & & & 4.259 0.039 \\
\hline
& No & 64 & 44.76 & 82 & 34.17 & 146 & 38.12 \\
\hline
& Total & 143 & 100.00 & 240 & 100.00 & 383 & 100.00 \\
\hline
& & N & \% & N & \% & N & \% & & & Pearson X2 and p value \\
\hline
Do you eat breakfast before all training/lifting sessions & Yes & 74 & 51.75 & 156 & 65.00 & 230 & 60.05 & & & 6.560 0.010 \\
\hline
& No & 69 & 48.25 & 84 & 35.00 & 153 & 39.95 \\
\hline
& Total & 143 & 100.00 & 240 & 100.00 & 383 & 100.00 \\
\hline
& & N & \% & N & \% & N & \% & & & Pearson X2 and p value \\
\hline
Do you eat breakfast before all competitions & Yes & 121 & 84.62 & 218 & 91.60 & 339 & 88.98 & & & 4.439 0.035 \\
\hline
& No & 22 & 15.38 & 20 & 8.40 & 42 & 11.02 \\
\hline
& Total & 143 & 100.00 & 238 & 100.00 & 381 & 100.00 \\
\hline
\end{tabular}}
\end{table}
|
PMC5070225_table_4
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{cal- Attribute} & \textbf{Importance (\%)} \\
\hline
Mar- Time & 23.58 \\
\hline
of Confidentiality & 21.30 \\
\hline
same Result & 20.78 \\
\hline
Feedback & 17.58 \\
\hline
Format & 16.75 \\
\hline
\end{tabular}}
\end{table}
|
PMC3440922_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Gene symbol} & \textbf{Entrez Gene ID} & \textbf{Forward primer 5' -› 3'} & \textbf{Reverse primer 5' -› 3'} & \textbf{ATa} \\
\hline
\multicolumn{5}{|l|}{mRNA quantification} \\
\hline
fabp1a & 791610 & TAAGCTGACAGCGTTTGTGAAGGG & AGATGCGTCTGCTGATCCTCTTGT & 60.0 \\
\hline
fabp1b.1 & 554095 & AAGCTGAAGGTGGTGCTGAACA & CACGTTTGCTGATGCGCTTGTA & 59.0 \\
\hline
fabp1b.2 & EB880179 & TGCCGTTCTCTGGGAAGTTTGAGT & TGACTTTGTCTCCGCTCAGCATCT & 61.0 \\
\hline
fabp7a & 58128 & TGTGCCACTTGGAAACTGGTTGAC & AACATTGCCTACTTGCCTGGTAGG & 60.0 \\
\hline
fabp7b & 407736 & AAACCACTGCTGATGACCGACACT & AGTGGTCTCTTTCCCATCCCACTT & 61.0 \\
\hline
fabp10a & 171481 & TTACGCTCAGGAGAACTACG & CTTCCTGATCATGGTGGTTC & 55.0 \\
\hline
fabp10b & 795210 & CGGCTCCAGAGCACTACATC & GTTCACTCATGTGCGGGAGC & 60.0 \\
\hline
fabp11a & 447944 & TGTGCAGAAACAGACCTGGGA & ACAGCCACCACATCACCCATCTT & 60.0 \\
\hline
fabp11b & 553579 & GCTGTCACTACATTCAAGACCTG & AGTTTACCATCCGCAAGGCTCA & 60.0 \\
\hline
acox1 & 449662 & AGTCAGCACGAGCTCTCTCC & GCCCTACAAAGTGAAAGGCA & 58.0 \\
\hline
rpl13$\alpha$ & 560828 & AGCAAGTGCTGTTGGGCCAC & GTGTGGCGGTGATGGCCTGG & 61.0 \\
\hline
\multicolumn{5}{|l|}{hnRNA quantification} \\
\hline
fabp1a & 791610 & ATCAATGGAGGTCAACGGCGAC & CAGCATGCGTGAAGCCGCCC & 62.5 \\
\hline
fabp1b.1 & 554095 & GAACTAACGTGTGCTGCTTGTG & CACGTTTGCTGATGCGCTTGTA & 57.0 \\
\hline
fabp7a & 58128 & CCATCCATCAGATTTCTATGTGGG & CATTATGCCTTCTCGTATGTGCG & 56.5 \\
\hline
fabp7b & 407736 & TTGGAAATGTGACCAAACCGACGC & TCGTCTCGAAAGGGAATGCAGTGT & 61.5 \\
\hline
fabp10a & 171481 & TCCAGCAGAACGGCAGCGAC & CGCCTGTAAAGTGAAGCCATTTCCA & 61.0 \\
\hline
fabp11a & 447944 & CCAAGCCGTTTTTGATGATGTGAG & GCTATTAATTTCCCATCCGACACC & 57.0 \\
\hline
acox1 & 449662 & GGCTACTCCCGCTGCAGCAG & GGCCTGAGGGTTGTTGGGCC & 63.0 \\
\hline
rpl13$\alpha$ & 560828 & ACCAACCCTTCCCGTGGACCA & AGCCAATGCTTGCTTCTACAACAGA & 61.5 \\
\hline
\end{tabular}}
\end{table}
|
PMC3483278_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Covariates} & \textbf{Beta} & \textbf{Std. Err} & \textbf{t} & \textbf{p-value} \\
\hline
(Constant) & 2.287 & .126 & 18.096 & .000 \\
\hline
Gender & 2.008 & .069 & 2.117 & .907 \\
\hline
Age & .002 & .002 & 1.511 & .131 \\
\hline
H1N1 & .288 & .037 & 7.890 & .000 \\
\hline
to H3N2 & 2.068 & .040 & 21.698 & .090 \\
\hline
B.Y & .045 & .033 & 1.356 & .175 \\
\hline
B.V & 2.021 & .029 & 2.714 & .475 \\
\hline
\end{tabular}}
\end{table}
|
PMC3558489_table_4
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
Refinement on F2 & Secondary atom site location: difference Fourier map \\
\hline
Least-squares matrix: full & Hydrogen site location: inferred from neighbouring sites \\
\hline
R[F2 $>$ 2$\sigma$(F2)] = 0.058 & H-atom parameters constrained \\
\hline
wR(F2) = 0.162 & w = 1/[$\sigma$2(Fo 2) + (0.0856P)2] where P = (Fo 2 + 2Fc 2)/3 \\
\hline
S = 0.95 & ($\Delta$/$\sigma$)max $<$ 0.001 \\
\hline
3124 reflections & $\Delta$$\rho$max = 0.31 e Å−3 \\
\hline
217 parameters & $\Delta$$\rho$min = −0.27 e Å−3 \\
\hline
Primary atom site location: structure-invariant direct methods & Extinction correction: none \\
\hline
\end{tabular}}
\end{table}
|
PMC2960035_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
& \multicolumn{2}{|l|}{\textbf{dvSalt30}} & \multicolumn{2}{|l|}{\textbf{ecox}} & \multicolumn{2}{|l|}{\textbf{shHeat5}} & \multicolumn{2}{|l|}{\textbf{shCold5}} \\
\hline
\textbf{Method} & \textbf{\#Genes} & \textbf{\%Agree} & \textbf{\#Genes} & \textbf{\%Agree} & \textbf{\#Genes} & \textbf{\%Agree} & \textbf{\#Genes} & \textbf{\%Agree} \\
\hline
1-gene (OpWise) & 220 & 100\% & 1062 & 98\% & 1002 & 97\% & 187 & 100\% \\
\hline
operon-wise & 401 & 99\% & 1318 & 100\% & 1284 & 99\% & 374 & 100\% \\
\hline
no-bias & 1090 & 90\% & 1269 & 98\% & 3020 & 87\% & 3063 & 70\% \\
\hline
SAM & 852 & 94\% & 957 & 99\% & 3348 & 83\% & 3258 & 68\% \\
\hline
\end{tabular}}
\end{table}
|
PMC1397872_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
& & & \multicolumn{3}{|l|}{\textbf{Peak location}} \\
\hline
\textbf{Brain regions} & & \textbf{Brodmann’s area} & \textbf{x} & \textbf{y} & \textbf{z} & \textbf{Peak t- score} & \textbf{Number of voxels} \\
\hline
MPFC & R & 11 & 9 & 60 & −18 & 3.78 & 18 \\
\hline
ACC & R & 10, 11 & 3 & 36 & −3 & 4.17 & 14 \\
\hline
Supramarginal gyrus & R & 2 & 63 & −33 & 27 & 4.78 & 13 \\
\hline
& R & 19 & 45 & −81 & 12 & −5.33 & 45 \\
\hline
Middle occipital gyrus & L & 19 & −42 & −84 & 6 & −4.85 & 15 \\
\hline
& & 17 & −18 & −99 & 3 & −3.74 & 12 \\
\hline
Superior occipital gyrus & R & 19 & 27 & −81 & 39 & −4.52 & 12 \\
\hline
& L & 19 & −21 & −90 & 27 & −5.59 & 47 \\
\hline
Cuneus & R & 17 & 15 & −78 & 12 & −4.23 & 12 \\
\hline
Postcentral gyrus & L & 2 & −30 & −45 & 60 & −4.78 & 12 \\
\hline
& & 48 & −48 & −218 & 30 & −5.16 & 12 \\
\hline
Cerebellum & L & – & −30 & −57 & −45 & −4.22 & 23 \\
\hline
\end{tabular}}
\end{table}
|
PMC5064334_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Region} & \textbf{Site} & \textbf{Geographic Coordinates} & \textbf{Accession \#s} & \textbf{Publication Source} & \textbf{On Fig. 1} \\
\hline
Alaska, USA & Toklat glacier & 63.39 N 149.91 W & JF719324-28, 31–38, JF729309 & This study & A \\
\hline
& Mendenhall glacier & 58.435837 N 134.5546 W & GQ396863, 949, 971 & Sattin et al. [58] & B \\
\hline
Colorado, USA & Arikaree glacier & 40.057276 N 105.6432 W & JF719322, 3, 9 & This study & C \\
\hline
Peru & Cordillera Vilcanota & 13.770123 S 71.07002 W & GQ306091 & Schmidt et al. [21] & D \\
\hline
Nunavut, Canada & John Evans glacier & 79.66 N 74 W & DQ228409, 3 & Skidmore et al. [17] & E \\
\hline
& John Evans glacier & 79.63 N 74.38 W & DQ628932-40, DQ530258 & Cheng et al. [22] & E \\
\hline
Germany & Schneeferner glacier & 47.42 N 10.98 E & EU978852 & Simon et al. [19] & F \\
\hline
Tain-Shen, China & Glacier no. 1 & 43.15 N 86.87 E & EF423322, 25, 30, 33, 40 & Wang et al. (unpubl.) & G \\
\hline
& Glacier no. 1 & 43.15 N 86.87 E & FJ979854, 9 & Zhang et al. (unpubl.) & G \\
\hline
Nepal & Zuntal glacial valley & 28.7210 N 83.9155 E & JF719330 & This study & H \\
\hline
Tibet, China & Puruogangri ice field & 33.89 N 89.15 E & DQ227793 & Zhang et al [18] & I \\
\hline
New Zealand & Fox glacier & 45.51 S 170.14 E & AY315176, 7 & Foght et al. [15] & J \\
\hline
& Franz Josef glacier & 43.48 S 170.21 E & AY315174, 5, 8 & Foght et al. [15] & J \\
\hline
Antarctica & Kamb ice stream & 82.25 S 145 W & FJ477327 & Lanoil et al. [16] & K \\
\hline
& Collins glacier & 73.21 S 66.97 E & EU636024-9 & Garcia et al. (unpubl.) & L \\
\hline
\end{tabular}}
\end{table}
|
PMC3163589_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{initially} & \textbf{Mean Change (SD) T1-T2 n = 87} & \textbf{Mean Change (SD) T2 -T3 n=74} & \textbf{Mean Change (SD) T1-T3 n=74} \\
\hline
\textbf{three} \\
\hline
\textbf{T2} \\
\hline
\multicolumn{4}{|l|}{All participants} \\
\hline
ratio Early & - 4.3 (6.0)* & - 0.8 (4.5) & - 4.4 (6.0)* \\
\hline
ef- Late & - 1.5 (6.4) & - 4.3 (4.7)* & - 5.3 (6.7)* \\
\hline
\multicolumn{4}{|l|}{group Female} \\
\hline
Early & - 4.4 (5.7)* & - 1.0 (4.6) & - 4.7 (5.3)* \\
\hline
covari- Late & - 2.2 (6.0) & - 4.3 (4.9)* & - 5.7 (6.7)* \\
\hline
\multicolumn{4}{|l|}{rela- Male} \\
\hline
with Early & - 4.1 (7.3) & - 0.1 (4.3) & - 3.4 (8.4) \\
\hline
a Late & + 0.6 (7.2) & - 4.4 (4.3)* & - 4.0 (6.6) \\
\hline
\multicolumn{4}{|l|}{Memorial} \\
\hline
Early & - 3.3 (7.7) & - 1.5 (6.4) & - 9.0 (9.9) * \\
\hline
Late & - 0.7 (6.2) & - 4.4 (5.0)* & - 5.8 (9.8) * \\
\hline
\multicolumn{4}{|l|}{Saskatchewan} \\
\hline
CI) Early & - 4.8 (3.5)* & + 0.2 (2.1) & - 3.7 (2.2)* \\
\hline
Late & - 3.9 (7.1) & - 2.6 (3.9) & - 6.3 (8.8) \\
\hline
\multicolumn{4}{|l|}{Dalhousie} \\
\hline
Early & - 4.3 (6.5)* & −1.0 (4.9) & - 4.2 (6.5)* \\
\hline
Late & - 1.0 (6.2) & - 4.8 (4.9)* & - 4.9 (5.0)* \\
\hline
\end{tabular}}
\end{table}
|
PMC3533989_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Home Exposure Variables∗} & \textbf{n (\%)} \\
\hline
\multicolumn{2}{|l|}{Q. 1 Water damage since Hurricane Katrina} \\
\hline
Yes & 180 (34.5) \\
\hline
No & 324 (62.2) \\
\hline
Mean number of months exposed to water damage & 9.1 \\
\hline
\multicolumn{2}{|l|}{Q. 2 Musty odor since Katrina} \\
\hline
Yes & 143 (27.4) \\
\hline
No & 354 (67.8) \\
\hline
Mean number of months exposed to musty odor & 9.6 \\
\hline
\multicolumn{2}{|l|}{Q. 3 Mold or mildew observed since Katrina} \\
\hline
Yes & 156 (29.8) \\
\hline
No & 351 (67.0) \\
\hline
Mean number of months observing mold or mildew & 10.0 \\
\hline
\multicolumn{2}{|l|}{Workplace Variables∗} \\
\hline
\multicolumn{2}{|l|}{Q. 4 Mold or mildew observed since Hurricane Katrina} \\
\hline
Yes & 98 (18.7) \\
\hline
No & 369 (70.6) \\
\hline
Mean number of months mold/mildew observed & 14.1 \\
\hline
\multicolumn{2}{|l|}{Q. 5 Ever worked in an occupation regularly exposed to mold} \\
\hline
Yes & 59 (11.9) \\
\hline
No & 367 (74.0) \\
\hline
Mean number of months working in occupation with mold & 15.2 \\
\hline
\multicolumn{2}{|l|}{Dampness index} \\
\hline
(1) answered yes to 1 question & 103 (19.5) \\
\hline
(2) answered yes to 2 questions & 86 (16.3) \\
\hline
(3) answered yes to 3 questions & 80 (15.1) \\
\hline
(4) answered yes to 4 questions & 19 (3.6) \\
\hline
(5) answered yes to all 5 questions & 9 (1.7) \\
\hline
Mean Months exposed to any of the dampness indicators & 13.3 \\
\hline
\end{tabular}}
\end{table}
|
PMC2948940_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \multicolumn{2}{|l|}{\textbf{Patients}} & \multicolumn{2}{|l|}{\textbf{Healthy controls}} \\
\hline
& \textbf{Female (n = 85)} & \textbf{Male (n = 44)} & \textbf{Female (n = 85)} & \textbf{Male (n = 44)} \\
\hline
Age (years)1 & 36.9 $\pm$ 10.8 & 34.1 $\pm$ 11.7 & 36.8 $\pm$ 10.9 & 34.1 $\pm$ 10.8 \\
\hline
Age at disease onset (years)1 & 28.9 $\pm$ 11.3 & 28.2 $\pm$ 9.8 & — & — \\
\hline
Disease duration (years)1, 2 & 6.6 $\pm$ 6.6 & 6.5 $\pm$ 6.9 & — & — \\
\hline
Depression (yes/no/not documented) & 27/40/38 & 19/19/6 & 0/85/0 & 0/44/0 \\
\hline
Antidepressants (yes/no/not documented)3 & 33/49/3 & 19/18/7 & 0/85/0 & 0/44/0 \\
\hline
Smoker status (yes/no/not documented) & 25/56/4 & 14/22/8 & Not documented & Not documented \\
\hline
\end{tabular}}
\end{table}
|
PMC4928917_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Basic knowledge of pregnancy} & \textbf{No. of subject with the correct answer} & \textbf{\%} \\
\hline
Antenatal care is important to check my condition during pregnancy (true) & 142 & 97.9 \\
\hline
The first antenatal care examination must be done within the 3 months (true) & 121 & 83.4 \\
\hline
Eating more iron containing food during pregnancy can prevent anemia (true) & 137 & 94.4 \\
\hline
Pregnant women need a supply of calcium (true) & 144 & 99.3 \\
\hline
Pregnant women must have their blood pressure checked during pregnancy (true) & 143 & 98.6 \\
\hline
Headache is normal sign during pregnancy (false) & 55 & 62 \\
\hline
Pregnant women needs to go to hospital when they have high blood pressure (true) & 130 & 89.6 \\
\hline
Bleeding during pregnancy is common and you don’t have to worry about it (false) & 17 & 88.3 \\
\hline
\end{tabular}}
\end{table}
|
PMC3298506_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
& \multicolumn{2}{|l|}{\textbf{United States}} & \textbf{Canada} & \textbf{Australia} & \textbf{South Korea} \\
\hline
& \textbf{Small molecules} & \textbf{Biologics} \\
\hline
Requirements for stay in approval & Patent litigation & Patent litigation after notice of commercial marketing of the biological product & Make application to the Federal Court & – & Patent litigation and statement that the request is made with respect to a genuine duly registered patent \\
\hline
Timing of request & Within 45 days of the date of receipt & – & Within 45 days after the date of receipt & _ & Within 45 days after the date of receipt \\
\hline
Judgment of request & – & Reviewed by the court & Reviewed by the court & _ & Reviewed by the MFDS \\
\hline
Specific measures & Administrative process by the FDA, a 30- month automatic stay-in-approval & Judicial process, a preliminary injunction & Quasi-administrative process by the MOH, a 24-month stay-in- approval & Injunction may be sought against sale but no process to prevent grant of marketing approval & Administrative process by the MFDS, a 9-month stay of sales \\
\hline
The starting point of the measures & The date of receiving the notification & – & The date on which the action is brought & – & The date of receiving the notification \\
\hline
Penalty against a misused stay of marketing approval & – & – & Yes, an MAH must compensate for any damage to an ANDA applicant & Yes, patent holder must provide compensation for losses by generics company and the relevant jurisdiction if unsuccessful in litigation & – \\
\hline
\end{tabular}}
\end{table}
|
PMC6201583_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Genus} & \textbf{Number of species} & \textbf{Minimum Distance (\%)} & \textbf{Maximum Distance (\%)} \\
\hline
Odontesthes & 2 & 0 & 0.62 \\
\hline
Pimelodus & 2 & 4.06 & 4.21 \\
\hline
Ageneiosus & 2 & 9.78 & 11.65 \\
\hline
Characidium & 2 & 12.4 & 13.73 \\
\hline
Astyanax & 2 & 15.21 & 16.77 \\
\hline
Crenicichla & 2 & 19.48 & 19.89 \\
\hline
\end{tabular}}
\end{table}
|
PMC4956254_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{AA} & \textbf{Solution \#} & \textbf{Theoretical Conc. (µg/mL)} & \textbf{Mean Observed Conc. (µg/mL)} & \textbf{n a} & \textbf{Precision (RSD \%)} & \textbf{Accuracy (Recovery \%)} \\
\hline
Leu & \multicolumn{3}{|l|}{1 31.20 29.21 2 160.00 163.94} & 9 & 7.13 & 93.61 \\
\hline
& & & & & 6.72 & 102.46 \\
\hline
Phe & \multicolumn{3}{|l|}{1 25.00 22.70 2 100.00 105.16} & 9 & 6.77 & 90.79 \\
\hline
& & & & & 10.51 & 105.16 \\
\hline
Trp & \multicolumn{3}{|l|}{1 33.00 29.86 2 143.00 139.63} & 9 & 6.86 & 90.49 \\
\hline
& & & & & 4.71 & 97.65 \\
\hline
\end{tabular}}
\end{table}
|
PMC6099655_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Gene (GSTM3) Loci} & \textbf{Chr:position} & \textbf{Forward primera} & \textbf{Reverse primera} & \textbf{Extension primer} & \textbf{Amplicon size (bp)} \\
\hline
rs1537236 & 1:109736350 & linker-GCCCATAGGCTGCTCTGC & linker- GCCTTAGGAAAAGTTGTAG & CACAAA GGAAAGATTT & 121 \\
\hline
rs3814309 & 1:109734781 & linker-GTGGCAAAACATGGCA GTTG & linker- CAGGGATACCCAGTGATGTC & TTAGCACCTTCTGTCTG & 78 \\
\hline
rs1109138 & 1:109735327 & linker-AGCTTCAAATTCCTGG GCTC & linker- ACCCCTGTCTCCCAAAAATT & GGACTATGCATGAGCAA & 69 \\
\hline
rs1055259 & 1:109734239 & linker-AGTGACCATCCCAACTTTGG & linker- CCATGGGGGTGCTAAAACCAC & TTTAACCCAGCTCATTAT & 119 \\
\hline
rs5776997 & 1:109736432 & linker-GGGGTAGGAGAAGTTT CTTT & linker- TACTCCACAGGCAGAGCAG & CTTTAAAGACGTAAAAAGAAAAAA & 86 \\
\hline
\end{tabular}}
\end{table}
|
PMC5980204_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Concept} & \textbf{Lig1} & \textbf{Lig3} & \textbf{Lig4} \\
\hline
classical concept & DNA replication & BER (short patch) & NHEJ \\
\hline
& BER (long patch) & mitochondria & V(D)J recombination \\
\hline
& HR & & class switch recombination \\
\hline
& NER \\
\hline
new concept & DNA replication & DNA replication & NHEJ \\
\hline
& BER (long patch) & BER (short patch) & V(D)J recombination \\
\hline
& HR & HR & class switch recombination \\
\hline
& NER & NER \\
\hline
& B-NHEJ & B-NHEJ \\
\hline
& (V(D)J recombination?) & (V(D)J recombination?) \\
\hline
& (class switch recombination?) & (class switch recombination?) \\
\hline
& & mitochondria \\
\hline
\end{tabular}}
\end{table}
|
PMC4488670_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\multicolumn{2}{|l|}{\textbf{Cell lines}} & \textbf{EMT} & \textbf{Apoptosis} & \textbf{Survival} \\
\hline
\textbf{T47D} & \textbf{control} & \textbf{No} & \textbf{No} & \textbf{Yes} \\
\hline
& Snail & Yes & Yes & No \\
\hline
& Twist & Yes & No & Yes \\
\hline
MCF7 & control & No & No & Yes \\
\hline
& Snail & Yes & Yes & No \\
\hline
& Twist & No & Yes & No \\
\hline
\end{tabular}}
\end{table}
|
PMC4837350_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& & \multicolumn{2}{|l|}{\textbf{Female N=1699}} & \multicolumn{2}{|l|}{\textbf{Male N=1522}} \\
\hline
\textbf{Health behaviour} & & \textbf{N} & \textbf{\%} & \textbf{N} & \textbf{\%} & \textbf{p-value} \\
\hline
Smoking & \multicolumn{5}{|l|}{Non-smoker 1081 63.6 918 60.3 Ex-smoker 219 12.9 228 15.0 Smoker 378 22.2 341 22.4 Missing 21 1.2 35 2.3} & 0.145 \\
\hline
\\
\hline
\\
\hline
\\
\hline
Alcohol & \multicolumn{5}{|l|}{Never 16 0.9 65 4.3 Less than once a week 673 39.6 305 20.0 Once a week 470 27.7 394 25.9 Several times every week 334 19.7 638 41.9 At least every day 16 0.9 65 4.3 Missing 7 0.4 11 0.7} & $<$0.001 \\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
Drug consumption & \multicolumn{5}{|l|}{No drug intake 1539 90.6 1275 83.8 Drug intake 117 6.9 198 13.0 Missing 43 2.5 49 3.2} & $<$0.001 \\
\hline
\\
\hline
\\
\hline
BMI & \multicolumn{5}{|l|}{Underweight 129 7.6 18 1.2 Normal weight 1305 76.8 1137 74.7 Overweight 205 12.1 352 23.1 Missing 60 3.5 15 1.0} & $<$0.001 \\
\hline
\\
\hline
\\
\hline
\\
\hline
Physical activity & \multicolumn{5}{|l|}{at least 3 times a week 539 31.7 780 51.2 1 to 2 times a week 691 40.7 463 30.4 Less than once a week 461 27.1 263 17.3 Missing 8 0.5 16 1.1} & $<$0.001 \\
\hline
\\
\hline
\\
\hline
\\
\hline
Importance of healthy nutrition & \multicolumn{5}{|l|}{Very important 429 25.3 292 19.2 Somewhat important 825 48.6 596 39.2 Important 374 22.0 432 28.4 Somewhat unimportant 59 3.5 142 9.3 Very unimportant 10 0.6 52 3.4 Missing 2 0.1 8 0.5} & $<$0.001 \\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\\
\hline
\end{tabular}}
\end{table}
|
PMC3544606_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Clinicopathological characteristics} & & \textbf{n percentile (\%)} \\
\hline
Gender & Male & 62 (69.7) \\
\hline
& Female & 27 (30.3) \\
\hline
Age (years) & $\leq$ 60 & 31 (34.8) \\
\hline
& $>$ 60 & 58 (65.2) \\
\hline
Gross classification & Ulcer & 56 (62.9) \\
\hline
& Eminence & 33 (37.1) \\
\hline
Histological type & Tubular & 64 (71.9) \\
\hline
& Papillary & 16 (18.0) \\
\hline
& Mucinous & 9 (10.1) \\
\hline
Pathologic differentiation & High & 16 (18.0) \\
\hline
& Moderate & 63 (70.8) \\
\hline
& Poor & 10 (11.2) \\
\hline
T stage & T1 & 5 (5.6) \\
\hline
& T2 & 36 (40.5) \\
\hline
& T3 & 46 (51.7) \\
\hline
& T4 & 2 (2.2) \\
\hline
N stage & N0 & 56 (62.9) \\
\hline
& N+ & 33 (37.1) \\
\hline
Cancer nodule & Positive & 10 (11.2) \\
\hline
& Negative & 79 (88.8) \\
\hline
EGFR & Positive & 63 (70.8) \\
\hline
& Negative & 26 (29.2) \\
\hline
\end{tabular}}
\end{table}
|
PMC6043992_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
\textbf{Variable} & \multicolumn{4}{|l|}{\textbf{Wealth quartile*}} \\
\hline
& \textbf{Most poor (n = 127)} & \textbf{Below average (n = 126)} & \textbf{Above average (n = 126)} & \textbf{Most wealthy (n = 125)} & \textbf{MW:MP**} & \textbf{c2} & \textbf{p-value} \\
\hline
Ability to save money & 43 (33.9\%) & 51 (40.5\%) & 29 (23.0\%) & 33 (26.4\%) & 0.8 & 15.2 & 0.002 \\
\hline
Low income without savings & 59 (46.4\%) & 44 (34.9\%) & 66 (52.4\%) & 54 (43.2\%) & 0.9 & 10.8 & 0.013 \\
\hline
Low income with savings & 19 (15.0\%) & 11 (8.7\%) & 9 (7.1\%) & 5 (4.0\%) & 0.3 & 15.2 & 0.002 \\
\hline
High income without savings & 25 (19.7\%) & 31 (24.6\%) & 31 (24.6\%) & 38 (30.4\%) & 1.5 & 15.0 & 0.003 \\
\hline
High income with savings & 24 (18.9\%) & 40 (31.8\%) & 20 (15.9\%) & 28 (22.4\%) & 1.2 & 11.1 & 0.011 \\
\hline
\end{tabular}}
\end{table}
|
PMC2942820_table_5
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{1} & \textbf{GDS Groups 2} & \textbf{3} & \textbf{p-value} \\
\hline
\\
\hline
Number Women (\%) & 21 (80.7) & 21 (84) & 21 (67.7) & 0.34 \\
\hline
Number isiXhosa (\%) & 22 (88.5) & 23 (95.7) & 30 (96.8) & 0.22 \\
\hline
Age median (IQR) & 30 (27-31) & 28 (25-32) & 30 (28-32) & 0.34 \\
\hline
Education median (IQR) & 12 (10-12) & 10 (10-12) & 9 (8-10) & 0.00* \\
\hline
CD4 One median (IQR) & 180 (146-199) & 182.5 (143-221) & 138 (100-205) & 0.32 \\
\hline
CD4_Two median (IQR) & 395 (271-465) & 340 (263-518) & 302 (156-388) & 0.07 \\
\hline
Duration of HAART in months median (IQR) & 11 (10-12) & 11 (10-14) & 10 (8-12) & 0.45 \\
\hline
CPE median (IQR) & 2 (1.5-2.5) & 2 (1.5-2.25) & 2 (1.5-2.5) & 0.98 \\
\hline
GDS Change median (IQR) & 0 (-0.67-0.67) & 0.13 (-0.67-0.27) & 0.6 (0.2-0.8) & 0.00* \\
\hline
\end{tabular}}
\end{table}
|
PMC3356227_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
& \multicolumn{5}{|l|}{\textbf{Image set}} \\
\hline
& \textbf{1} & \textbf{2} & \textbf{3} & \textbf{4} & \textbf{5} \\
\hline
Smallest gland visualized & 260 & 260 & 420 & 550 & 260 \\
\hline
Mean weight of FN (mg) & 300 & 420 & 485 & 420 & 300 \\
\hline
Mean weight of TP (mg) & 560 & 570 & 960 & 830 & 560 \\
\hline
𝑃𝑃 (FN versus TP) & 0.002 & $<$0.001 & 0.046 & 0.026 & $<$0.001 \\
\hline
\end{tabular}}
\end{table}
|
PMC3564434_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
\textbf{Model} & \textbf{Genotype} & \textbf{Case} & \textbf{Control} & \textbf{OR* (95\% CI**)} & \textbf{p-value} & \textbf{AIC***} & \textbf{BIC****} \\
\hline
Codominant & \multicolumn{4}{|l|}{C/C 76 (67.9\%) 50 (53.8\%) 1.00 C/G 16 (14.3\%) 16 (17.2\%) 1.03 (0.38-2.76) G/G 20 (17.9\%) 27 (29\%) 4.03 (1.51-10.79)} & 0.013 & 199.5 & 219.4 \\
\hline
\\
\hline
\\
\hline
Dominant & \multicolumn{4}{|l|}{C/C 76 (67.9\%) 50 (53.8\%) 1.00 C/G-G/G 36 (32.1\%) 43 (46.2\%) 2.11 (1.00-4.48)} & 0.048 & 202.3 & 218.9 \\
\hline
\\
\hline
Recessive & \multicolumn{4}{|l|}{C/C-C/G 92 (82.1\%) 66 (71\%) 1.00 G/G 20 (17.9\%) 27 (29\%) 4.01 (1.53-10.53)} & 0.0031 & 197.5 & 214.1 \\
\hline
\\
\hline
Overdominant & \multicolumn{4}{|l|}{C/C-G/G 96 (85.7\%) 77 (82.8\%) 1.00 C/G 16 (14.3\%) 16 (17.2\%) 0.75 (0.29-1.93)} & 0.55 & 205.9 & 222.5 \\
\hline
\\
\hline
Log-additive & --- & --- & --- & 1.84 (1.16-2.93) & 0.0079 & 199.2 & 215.8 \\
\hline
\end{tabular}}
\end{table}
|
PMC5960056_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{PCT test} & \textbf{Cutoff 0.5 ng /mL} & \textbf{Cutoff 2.0 ng/mL} & \textbf{Cutoff 10 ng/mL} \\
\hline
Sensitivity & 0.52 [0.37–0.67] & 0.20 [0.10–0.34] & 0.02 [0.00–0.13] \\
\hline
Specificity & 0.76 [0.66–0.83] & 0.91 [0.84–0.95] & 0.97 [0.92–0.99] \\
\hline
Positive predictive value & 0.47 [0.33–0.61] & 0.47 [0.25–0.71] & 0.25 [0.01–0.78] \\
\hline
Negative predictive value & 0.79 [0.70–0.86] & 0.73 [0.65–0.80] & 0.71 [0.63–0.78] \\
\hline
\end{tabular}}
\end{table}
|
PMC2792948_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Gene name} & \textbf{Gene annotation} & \textbf{RefSeq ID} & \textbf{Sequence} & \textbf{Amplicon size} \\
\hline
DEFA 1-3* & Defensin, alpha 1 to 3 & NM_005218.3 & CCTGCCTAGCTAGAGGATCTGTG & 222 bp \\
\hline
& & NM_005217.2 & TGTTTTTCCTTGAGCCTGGA \\
\hline
DEFA 6* & Defensin, alpha 6, Paneth cell-specific & NM_001926.2 & CTCAAGTCTTAGAGCTTTGGGCT & 198 bp \\
\hline
& & & GGACACACGACAGTTTCCTTC \\
\hline
b-actin* & Beta actin & NM_001101 & AGAGCCTCGCCTTTGCCGAT & 160 bp \\
\hline
& & & CCCACGATGGAGGGGAAGAC \\
\hline
\end{tabular}}
\end{table}
|
PMC2984430_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Country} & \textbf{Number of authors} \\
\hline
Poland & 109 \\
\hline
Japan & 62 \\
\hline
China & 38 \\
\hline
Canada & 10 \\
\hline
Germany & 10 \\
\hline
Russia & 4 \\
\hline
USA & 4 \\
\hline
Austria & 3 \\
\hline
Italy & 2 \\
\hline
Netherlands & 2 \\
\hline
Ukraine & 2 \\
\hline
Belgium & 1 \\
\hline
Czech Republic & 1 \\
\hline
Denmark & 1 \\
\hline
Finland & 1 \\
\hline
Israel & 1 \\
\hline
Myanmar & 1 \\
\hline
Spain & 1 \\
\hline
Total & 253 \\
\hline
\end{tabular}}
\end{table}
|
PMC6044251_table_8
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
& \multicolumn{3}{|l|}{\textbf{Clinical phases}} & \textbf{Total} & \textbf{p} \\
\hline
& \textbf{Indeterminate (n = 16)} & \textbf{CPND (n = 17)} & \textbf{CPD (n = 21)} \\
\hline
& & & & \textbf{(n = 54)} \\
\hline
Age & 57.8 $\pm$ 11.9 & 54.3 $\pm$ 10.3 & 54.7 $\pm$ 11.3 & 55.5 $\pm$ 11.1 & 0.61 \\
\hline
Male & 3 (18.7 \%) & 7 (41.1 \%) & 16 (76.1 \%) & 26 (48.1 \%) & 0.02 \\
\hline
FC NYHA = I & 16 (100 \%) & 14 (82.4 \%) & 1 (4.8 \%) & 31 (57.4 \%) & $<$0.001 \\
\hline
FC NYHA $>$ I & 0 (0) & 3 (17.6 \%) & 20 (95.2 \%) & 23 (42.6 \%) & $<$0.001 \\
\hline
RVEDVi (ml/m2) & 67.7 $\pm$ 14.9 & 70.4 $\pm$ 12.2 & 78.0 $\pm$ 22.7 & 72.6 $\pm$ 18.0 & 0.19 \\
\hline
RVESVi (ml/m2) & 25.9a $\pm$ 5.6 & 32.0 $\pm$ 9.1 & 40.8a $\pm$ 21.7 & 33.6 $\pm$ 15.8 & 0.01 \\
\hline
RVEF (\%) & 60.9a $\pm$ 7.1 & 54.7 $\pm$ 7.9 & 49.2a $\pm$ 12.8 & 54.4 $\pm$ 10.9 & 0.04 \\
\hline
LVEDVi (ml/m2) & 72.0a $\pm$ 15.4 & 84.6b $\pm$ 22.7 & 137.0a, b $\pm$ 44.0 & 101.4 $\pm$ 42.6 & $<$0.001 \\
\hline
LVESVi (ml/m2) & 24.9a $\pm$ 6.3 & 39.7b $\pm$ 19.5 & 90.4a, b $\pm$ 42.3 & 55.0 $\pm$ 40.6 & $<$0.001 \\
\hline
LVEF (\%) & 65.0a $\pm$ 5.7 & 54.0a $\pm$ 12.0 & 35.8a $\pm$ 10.8 & 50.2 $\pm$ 15.8 & $<$0.001 \\
\hline
Mass index(g/m2) & 55.2a $\pm$ 10.5 & 70.9 $\pm$ 15.8 & 82.2a $\pm$ 27.6 & 70.6 $\pm$ 22.8 & 0.01 \\
\hline
\end{tabular}}
\end{table}
|
PMC4652401_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{All oligo arrays (service)} & \textbf{Oligo arrays following normal karyotype} & \textbf{Oligo arrays as first line test} \\
\hline
Total patients & 2414 & 1245 & 1169 \\
\hline
Abnormal patients & 585 (24\%) & 325 (26\%) & 260 (22\%) \\
\hline
- inherited & 169 & 97 & 72 \\
\hline
- de novo & 63 & 52 & 11 \\
\hline
- unknown inheritance & 353 & 176 & 177 \\
\hline
\end{tabular}}
\end{table}
|
PMC2885406_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Method} & \textbf{100\%} & \textbf{50\%} & \textbf{20\%} & \textbf{10\%} \\
\hline
SSCS & 2.16 & 1.42 & 1.22 & 1.17 \\
\hline
EDCS & 2.44 & 1.41 & 1.1 & 1.08 \\
\hline
ResNet & 0.136 & 0.132 & 0.131 & 0.131 \\
\hline
GoogLeNet & 0.100 & 0.098 & 0.096 & 0.093 \\
\hline
VDCNs & 0.300 & 0.295 & 0.291 & 0.288 \\
\hline
Ours & 1.230 & 0.200 & 0.048 & 0.022 \\
\hline
\end{tabular}}
\end{table}
|
PMC5712811_table_4
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
Refinement on F2 & Primary atom site location: structure-invariant direct methods \\
\hline
Least-squares matrix: full & Secondary atom site location: difference Fourier map \\
\hline
R[F2 $>$ 2$\sigma$(F2)] = 0.064 & Hydrogen site location: inferred from neighbouring sites \\
\hline
wR(F2) = 0.175 & H-atom parameters constrained \\
\hline
S = 1.09 & w = 1/[$\sigma$2(Fo 2) + (0.0818P)2 + 3.9232P] where P = (Fo 2 + 2Fc 2)/3 \\
\hline
7026 reflections & ($\Delta$/$\sigma$)max = 0.001 \\
\hline
651 parameters & $\Delta$$\rho$max = 0.64 e Å−3 \\
\hline
0 restraints & $\Delta$$\rho$min = −0.26 e Å−3 \\
\hline
\end{tabular}}
\end{table}
|
PMC2979682_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{RIP} & \multicolumn{2}{|l|}{\textbf{Source}} & \textbf{Against viruses} & \textbf{Reference} \\
\hline
& \textbf{Scientific name} & \textbf{Tissue} \\
\hline
Alpha-momorcharin & Momordica charantia & Seeds & Chilli veinal mottle virus, Cucumber mosaic virus, Tobacco mosaic virus, Turnip mosaic potyvirus & Zhu et al., 2013; Yang et al., 2016 \\
\hline
PAP & Phytolacca americana & Leaves & Tobacco mosaic virus & Dallal and Irvin, 1978; Zhu et al., 2016 \\
\hline
New single-chain RIPs & Basella rubra & Seeds & Artichoke mottled crinkle virus & Bolognesi et al., 1997 \\
\hline
New single-chain RIPs & Bougainvillea spectabilis & Leaves & Artichoke mottled crinkle virus & Bolognesi et al., 1997 \\
\hline
CCP 25 & Celosia cristata & Leaves & Brome mosaic virus, Pokeweed mosaic virus & Baranwal et al., 2002 \\
\hline
27-kDa RIP & Amaranthus tricolor & Leaves & Sunn-hemp rosette virus & Roy et al., 2006 \\
\hline
RIP & Bougainvillea xbuttiana & Leaves & Sunn-hemp rosette virus & Choudhary N.L. et al., 2008 \\
\hline
ME1 & Mirabilis expansa & Roots & Tobacco mosaic virus, Brome mosaic virus & Vivanco and Tumer, 2003 \\
\hline
Clerodendrum aculeatum-systemic resistance inducing (CA-SRI) protein & Clerodendrum aculeatum & Leaves & Tobacco mosaic virus, Sunn-hemp rosette virus & Verma et al., 1996; Kumar et al., 1997 \\
\hline
CAP-34 & Clerodendrum aculeatum & Leaves & Papaya ringspot virus & Srivastava et al., 2009 \\
\hline
CIP-29 & Clerodendrum inerme & Leaves & Tobacco mosaic virus & Prasad et al., 1995; Olivieri et al., 1996 \\
\hline
BDP-30 & Boerhavia diffusa & Roots & Tobacco mosaic virus & Srivastava et al., 2015 \\
\hline
PAP I & Phytolacca americana & Leaves & Zucchini yellow mosaic virus & Sipahio ˘glu et al., 2017 \\
\hline
\end{tabular}}
\end{table}
|
PMC5811460_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Type of sample} & \textbf{Sample no.} & \multicolumn{2}{|l|}{\textbf{Results, CFU l−1 (Log10)}} \\
\hline
& & \textbf{Culture method} & \textbf{IMS method} \\
\hline
Water Matrix & 1 & ND & ND \\
\hline
& 2 & ND & ND \\
\hline
& 3 & ND & ND \\
\hline
L.pneumophila & 4 & 3.3 & 3.4 \\
\hline
& 5 & 3.4 & 3.5 \\
\hline
& 6 & 3.1 & 3.7 \\
\hline
Microbiota I & 7 & 3.0 & 3.3 \\
\hline
& 8 & 3.5 & 3.7 \\
\hline
& 9 & ND & 3.7 \\
\hline
Microbiota II & 10 & ND & 2.5 \\
\hline
& 11 & ND & 3.1 \\
\hline
& 12 & ND & 3.5 \\
\hline
\end{tabular}}
\end{table}
|
PMC4436101_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Order/Family} & \textbf{Species} & \multicolumn{2}{|l|}{\textbf{La Parva}} & \multicolumn{2}{|l|}{\textbf{Piedra Numerada}} \\
\hline
& & \textbf{N} & \textbf{\%} & \textbf{N} & \textbf{\%} \\
\hline
\multicolumn{6}{|l|}{Lepidoptera} \\
\hline
Nymphalidae & Faunula leucoglene & & & 34 & 72.3 \\
\hline
& Yramea lathonioides & 2 & 3.4 \\
\hline
\multicolumn{6}{|l|}{Diptera} \\
\hline
Bombyliidae & Villa sp. & 2 & 3.4 & 2 & 4.3 \\
\hline
& Villa gayi & 2 & 3.4 \\
\hline
& Villa semifuscata & 2 & 3.4 \\
\hline
& Sericosoma irwini & 4 & 6.8 \\
\hline
& Lyophlaeba sp. & 2 & 3.4 \\
\hline
& Triploechus bellus & 1 & 1.7 \\
\hline
Tachinidae & Tachinidae sp. & 11 & 18.6 & 11 & 23.4 \\
\hline
Syrphidae & Scaeva melanostoma & 2 & 3.4 \\
\hline
\multicolumn{6}{|l|}{Hymenoptera} \\
\hline
Megachilidae & Megachile sp. & 2 & 3.4 \\
\hline
Andrenidae & Lipanthus sp. & 5 & 8.5 \\
\hline
\multicolumn{6}{|l|}{Coleoptera} \\
\hline
Curculionidae & Arthrobrachus sp. & 24 & 40.7 \\
\hline
Total & & 59 & 100\% & 47 & 100\% \\
\hline
Total number of taxa & & 12 & & 3 \\
\hline
\end{tabular}}
\end{table}
|
PMC3088671_table_3
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Coverage} & \textbf{Pool Size} & \textbf{Match} & \textbf{Relocation} & \textbf{Inversion} & \textbf{Redundancy} & \textbf{Coverage} & \textbf{Scaffold N50} & \textbf{Number of scaffolds} \\
\hline
15L + 5P (3kb) & 3M & 0.506 & 0.872 & 0.734 & 0.835 & 76.38\% & 52,719 & 140 \\
\hline
15L + 5P (3kb) & 6M & 0.503 & 0.857 & 0.679 & 0.832 & 79.31\% & 40,526 & 320 \\
\hline
15L + 5P (3kb) & 9M & 0.502 & 0.847 & 0.687 & 0.820 & 80.33\% & 37,394 & 485 \\
\hline
15L + 5P (3kb) & 12M & 0.501 & 0.855 & 0.674 & 0.815 & 82.39\% & 37,122 & 577 \\
\hline
15L + 2.5P (3kb) + 2.5P (8 kb) & 3M & 0.511 & 0.717 & 0.728 & 0.818 & 85.83\% & 104,440 & 94 \\
\hline
15L + 2.5P (3kb) + 2.5P (8kb) & 6M & 0.504 & 0.700 & 0.733 & 0.799 & 84.25\% & 104,094 & 216 \\
\hline
15L + 2.5P (3 kb) + 2.5P (8 kb) & 9M & 0.503 & 0.752 & 0.703 & 0.807 & 85.54\% & 76,589 & 337 \\
\hline
15L + 2.5P (3kb) + 2.5P (8kb) & 12M & 0.502 & 0.815 & 0.717 & 0.778 & 86.36\% & 69,622 & 432 \\
\hline
\end{tabular}}
\end{table}
|
PMC3224119_table_4
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Feature Selection Algorithm} & \textbf{Selected Features} & \textbf{Best CV rate} \\
\hline
SVM with No Feature Selection & & 95 \\
\hline
SVM with F-score Selection & 3,6,7,9,10,39,52,57,59,60,72,80,81,89,90 & 100.0 \\
\hline
Correlation Based Selection & 3,6,10,12,14,15,37,39,59,69 & 100.0 \\
\hline
Relief Attribute Evaluation & 7,39,56,57,59,60,80,81,89,90 & 97.5 \\
\hline
Symmetrical Uncertainty & 15,39 & 100.0 \\
\hline
Consistency Subset Evaluation & 15 & 100.0 \\
\hline
\end{tabular}}
\end{table}
|
PMC3293912_table_5
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Primers} & \textbf{Upper primer sequence (5′-3′)} & \textbf{Lower primer sequence (5′-3′)} \\
\hline
COI-COIII & GGAAATTGACTTGTGCCT & TTGTATGTTTACCTTGGA \\
\hline
COIII-ND4 & AAAGGATTACGATGAGGT & GGTCTTGTTATTGGTGGA \\
\hline
ND4-Cytb & CGTCTATGTAAACGCTCA & ATAAGGGTTTTCTACTGGT \\
\hline
Cytb-12S & TTTTACATCAAACAGGA & ACTAGGATTAGATACCC \\
\hline
12S-COI & GAAACACTTTCCAGTACCT & CTAAACCAATTCAACATCC \\
\hline
\end{tabular}}
\end{table}
|
PMC3335176_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& & \multicolumn{3}{|l|}{\textbf{Statistics}} & \multicolumn{2}{|l|}{\textbf{95\% Confidence}} \\
\hline
& & \textbf{n} & \textbf{Mean} & \textbf{SD} & \textbf{Interval} & \textbf{for Mean} \\
\hline
\textbf{to Clusters} & \textbf{Group} & & & & \textbf{Lower Bound} & \textbf{Upper Bound} \\
\hline
\textbf{at} \\
\hline
by Understanding & Patients & 19 & 3.31 & .64 & 3.00 & 3.61 \\
\hline
16 & Professionals & 11 & 3.69 & .36 & 3.45 & 3.94 \\
\hline
& Total & 30 & 3.45 & .58 & 3.23 & 3.66 \\
\hline
less Acceptance & Patients & 18 & 3.31 & .74 & 2.94 & 3.67 \\
\hline
& Professionals & 12 & 3.12 & .64 & 2.72 & 3.53 \\
\hline
& Total & 30 & 3.23 & .69 & 2.97 & 3.49 \\
\hline
Adjustment & Patients & 19 & 3.11 & .64 & 2.79 & 3.42 \\
\hline
& Professionals & 12 & 3.08 & .62 & 2.69 & 3.48 \\
\hline
& Total & 31 & 3.10 & .63 & 2.87 & 3.33 \\
\hline
to Respect & Patients & 19 & 2.91 & .58 & 2.63 & 3.19 \\
\hline
& Professionals & 12 & 2.98 & .75 & 2.50 & 3.46 \\
\hline
& Total & 31 & 2.94 & .64 & 2.70 & 3.17 \\
\hline
Regulation & Patients & 14 & 2.87 & .51 & 2.58 & 3.17 \\
\hline
& Professionals & 12 & 2.26 & .45 & 1.98 & 2.54 \\
\hline
& Total & 26 & 2.59 & .57 & 2.36 & 2.82 \\
\hline
Confidence & Patients & 19 & 3.04 & .49 & 2.80 & 3.27 \\
\hline
& Professionals & 12 & 3.10 & .50 & 2.78 & 3.42 \\
\hline
& Total & 31 & 3.06 & .49 & 2.88 & 3.24 \\
\hline
Self-esteem & Patients & 19 & 2.72 & .78 & 2.34 & 3.09 \\
\hline
& Professionals & 12 & 2.59 & .71 & 2.14 & 3.05 \\
\hline
& Total & 31 & 2.67 & .74 & 2.40 & 2.94 \\
\hline
Autonomy & Patients & 19 & 3.01 & .43 & 2.80 & 3.22 \\
\hline
& Professionals & 12 & 2.96 & .39 & 2.71 & 3.21 \\
\hline
& Total & 31 & 2.99 & .41 & 2.84 & 3.14 \\
\hline
\end{tabular}}
\end{table}
|
PMC3419208_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Factor} & \textbf{R2} & \textbf{P-value} \\
\hline
Fasting plasma glucose & 0.0120 & NS \\
\hline
HbA1c & 0.0731 & .040 \\
\hline
Systolic blood pressure & 0.0133 & NS \\
\hline
Diastolic blood pressure & 0.0301 & NS \\
\hline
Total cholesterol (TC) & 0.0424 & NS \\
\hline
HDL-C & 0.0042 & NS \\
\hline
LDL-C & 0.0258 & NS \\
\hline
Triglyceride (TG) & 0.0588 & NS \\
\hline
Duration of diabetes & 0.0150 & NS \\
\hline
Age & 0.0367 & NS \\
\hline
BMI & 0.0174 & NS \\
\hline
Gender & 0.0151 & NS \\
\hline
\end{tabular}}
\end{table}
|
PMC2656910_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \textbf{Theoretical} & \textbf{Firnberg et al. results [24]} & \multicolumn{2}{|l|}{\textbf{QuikChange Primers}} & \multicolumn{2}{|l|}{\textbf{Scripted Pfunkel Primers}} \\
\hline
& & \textbf{Plated} & \textbf{Plated} & \textbf{Culture} & \textbf{Plated} & \textbf{Culture} \\
\hline
Sequences (reads) & & 787,488 & 414,410 & 319,179 & 510,126 & 436,135 \\
\hline
\multicolumn{7}{|l|}{NNN primer base composition} \\
\hline
T & 25.0\% & 17.1\% & 15.2\% & 16.7\% & 22.8\% & 19.2\% \\
\hline
A & 25.0\% & 18.3\% & 14.0\% & 15.7\% & 20.2\% & 19.7\% \\
\hline
C & 25.0\% & 18.3\% & 17.5\% & 18.5\% & 16.8\% & 19.8\% \\
\hline
G & 25.0\% & 46.3\% & 53.3\% & 49.0\% & 40.2\% & 41.4\% \\
\hline
\multicolumn{7}{|l|}{Percent of possible codon substitiutions observed} \\
\hline
1-base substitution & & 99.6\% & 100.0\% & 100.0\% & 100.0\% & 100.0\% \\
\hline
2-base substitutions & & 97.7\% & 99.6\% & 96.4\% & 98.6\% & 83.7\% \\
\hline
3-base substitutions & & 95.3\% & 98.7\% & 88.3\% & 97.3\% & 54.4\% \\
\hline
All substitutions & & 97.0\% & 99.3\% & 93.5\% & 98.3\% & 73.5\% \\
\hline
\multicolumn{7}{|l|}{Percent of reads with} \\
\hline
No nonsynonymous mutations & 1.6\% & 26.2\% & 22.4\% & 55.0\% & 62.6\% & 87.0\% \\
\hline
One nonsynonymous mutation & 98.4\% & 56.7\% & 70.6\% & 40.0\% & 34.1\% & 12.0\% \\
\hline
Multiple nonsynonymous mutations & 0.0\% & 17.1\% & 7.0\% & 5.0\% & 3.3\% & 1.0\% \\
\hline
Coverage of possible single nonsynonymous mutations & & & 99.9\% & 98.0\% & 99.5\% & 89.1\% \\
\hline
\end{tabular}}
\end{table}
|
PMC4366243_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Items} & \textbf{FESm (n = 61)} & \textbf{FESf (n = 63)} & \textbf{HCm (n = 50)} & \textbf{HCf (n = 52)} & \textbf{p} \\
\hline
Age & 24.31 (6.57) & 24.62 (6.82) & 24.80 (6.74) & 24.71 (6.98) & 0.982 \\
\hline
Education years & 13.13 (2.49) & 12.94 (2.49) & 13.77 (2.91) & 13.40 (2.55) & 0.366 \\
\hline
HM-tran (mm) & 0.13 (0.14) & 0.11 (0.13) & 0.11 (0.11) & 0.10 (0.10) & 0.099 \\
\hline
HM-rota (degree) & 0.12 (0.12) & 0.11 (0.14) & 0.11 (0.09) & 0.11 (0.11) & 0.649 \\
\hline
Total & 87.59 (17.07) & 89.27 (17.04) & – & – & 0.597 \\
\hline
Positive & 14.74 (4.40) & 15.77 (4.24) & – & – & 0.200 \\
\hline
Negative & 16.58 (7.73) & 14.85 (8.39) & – & – & 0.250 \\
\hline
D/C & 9.12 (2.75) & 9.48 (2.96) & – & – & 0.497 \\
\hline
Excited & 9.93 (3.85) & 11.32 (4.13) & – & – & 0.063 \\
\hline
Depressed & 6.19 (3.08) & 6.12 (2.71) & – & – & 0.887 \\
\hline
DUP (months) & 8.19 (8.97) & 5.50 (8.03) & – & – & 0.118 \\
\hline
Age of Onset & 23.24 (6.65) & 23.76 (6.64) & – & – & 0.689 \\
\hline
\end{tabular}}
\end{table}
|
PMC4519942_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Sample Number} & \textbf{Total carbonate [wt.\%]} & \textbf{Aragonite [wt.\%]} & \textbf{Calcite magnesian [wt.\%]} & \textbf{Calcite [wt.\%]} & \textbf{Quartz [wt.\%]} & \textbf{Halite [wt.\%]} & \textbf{Gypsum [wt.\%]} & \textbf{Orthoclase [wt.\%]} & \textbf{Sphalerite [wt.\%]} & \textbf{Kaolinite [wt.\%]} \\
\hline
GBS-01 & 0 & 0 & 0 & 0.0 & 80.5 & 1.2 & 0 & 18.3 & 0 & 0 \\
\hline
GBS-02 & 32.0 & 11.1 & 20.9 & 0.0 & 12.9 & 12.2 & 42.6 & 0 & 0.3 & 0 \\
\hline
GBS-04 & 96.3 & 3.9 & 85.3 & 7.1 & 3.7 & 0 & 0 & 0 & 0 & 0 \\
\hline
GBS-05 & 99.3 & 34.9 & 56.2 & 8.2 & 0.7 & 0 & 0 & 0 & 0 & 0 \\
\hline
GBS-06 & 98.9 & 53.3 & 42.3 & 3.3 & 1.1 & 0 & 0 & 0 & 0 & 0 \\
\hline
GBS-07 & 80.9 & 59.7 & 17.3 & 3.9 & 16.2 & 0 & 2.9 & 0 & 0 & 0 \\
\hline
GBS-08 & 65.3 & 39.0 & 23.1 & 3.2 & 19.9 & 0 & 14.7 & 0 & 0 & 0 \\
\hline
GBS-09 & 73.9 & 47.2 & 21.3 & 5.4 & 24.9 & 0 & 0.1 & 0 & 0 & 1.1 \\
\hline
GBS-10 & 73.0 & 46.3 & 23.9 & 2.8 & 23.4 & 0 & 3.7 & 0 & 0 & 0 \\
\hline
GBS-11 & 68.3 & 42.0 & 23.5 & 2.8 & 31.7 & 0 & 0 & 0 & 0 & 0 \\
\hline
GBS-12 & 90.6 & 42.8 & 45.5 & 2.3 & 9.5 & 0 & 0 & 0 & 0 & 0 \\
\hline
GBS-13 & 78.3 & 47.0 & 30.7 & 0.6 & 21.6 & 0 & 0.1 & 0 & 0 & 0 \\
\hline
GBS-14 & 88.4 & 56.6 & 29.1 & 2.7 & 11.5 & 0 & 0 & 0 & 0 & 0 \\
\hline
GBS-15 & 78.9 & 38.3 & 38.3 & 2.3 & 21.1 & 0 & 0 & 0 & 0 & 0 \\
\hline
GBS-16 & 86.2 & 30.3 & 54.2 & 1.7 & 13.6 & 0 & 0 & 0 & 0 & 0 \\
\hline
DJB-01 & 55.4 & 19.0 & 33.7 & 2.7 & 44.5 & 0 & 0 & 0 & 0 & 0 \\
\hline
DJB-02 & 19.0 & 7.8 & 8.0 & 3.2 & 81.0 & 0 & 0 & 0 & 0 & 0 \\
\hline
DJB-03 & 27.8 & 7.3 & 18.8 & 1.7 & 72.2 & 0 & 0 & 0 & 0 & 0 \\
\hline
DJB-04 & 43.5 & 27.4 & 13.2 & 2.9 & 56.4 & 0 & 0 & 0 & 0 & 0 \\
\hline
DJB-05 & 68.3 & 45.7 & 19.8 & 2.8 & 31.7 & 0 & 0 & 0 & 0 & 0 \\
\hline
DJB-06 & 61.3 & 27.2 & 31.7 & 2.4 & 38.7 & 0 & 0 & 0 & 0 & 0 \\
\hline
DJB-07 & 79.0 & 44.5 & 30.6 & 3.9 & 21.0 & 0 & 0 & 0 & 0 & 0 \\
\hline
DJB-08 & 61.5 & 36.1 & 23.1 & 2.3 & 38.5 & 0 & 0 & 0 & 0 & 0 \\
\hline
DJB-09 & 71.0 & 41.4 & 26.7 & 2.9 & 28.9 & 0 & 0 & 0 & 0 & 0 \\
\hline
DJB-10 & 62.7 & 37.1 & 23.0 & 2.6 & 37.4 & 0 & 0 & 0 & 0 & 0 \\
\hline
DJB-11 & 88.5 & 42.0 & 42.9 & 3.6 & 11.5 & 0 & 0 & 0 & 0 & 0 \\
\hline
DJB-12 & 86.8 & 48.3 & 36.1 & 2.4 & 13.2 & 0 & 0 & 0 & 0 & 0 \\
\hline
DJB-13 & 89.7 & 50.4 & 36.0 & 3.3 & 10.2 & 0 & 0 & 0 & 0 & 0 \\
\hline
DJB-14 & 79.2 & 39.4 & 36.7 & 3.1 & 20.8 & 0 & 0 & 0 & 0 & 0 \\
\hline
DJB-15 & 96.5 & 55.4 & 36.2 & 4.9 & 3.5 & 0 & 0 & 0 & 0 & 0 \\
\hline
\end{tabular}}
\end{table}
|
PMC5957445_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Nutrients and food groups} & \multicolumn{2}{|l|}{\textbf{ICC (FFQ1 vs FFQ2)}} \\
\hline
& \textbf{Crude a} & \textbf{Energy-adjusted b} \\
\hline
Energy (kcal) & 0.64 & - \\
\hline
Protein (g) & 0.59 & 0.42 \\
\hline
Fat (g) & 0.43 & 0.38 \\
\hline
Carbohydrates (g) & 0.59 & 0.47 \\
\hline
Fiber (g) & 0.49 & 0.33 \\
\hline
Retinol (mg) & 0.62 & 0.34 \\
\hline
Thiamine (mg) & 0.52 & 0.43 \\
\hline
Riboflavin (mg) & 0.74 & 0.44 \\
\hline
Niacin (mg) & 0.65 & 0.44 \\
\hline
Vitamin C (mg) & 0.43 & 0.32 \\
\hline
Vitamin E (mg) & 0.53 & 0.33 \\
\hline
Calcium (mg) & 0.61 & 0.45 \\
\hline
Iron (mg) & 0.62 & 0.43 \\
\hline
Zinc (mg) & 0.58 & 0.37 \\
\hline
Cereal (g) & 0.62 & 0.43 \\
\hline
Vegetables (g) & 0.58 & 0.41 \\
\hline
Fruit (g) & 0.59 & 0.35 \\
\hline
Red meat (g) & 0.73 & 0.43 \\
\hline
White meat (g) & 0.65 & 0.35 \\
\hline
Eggs (g) & 0.60 & 0.43 \\
\hline
Milk (g) & 0.71 & 0.40 \\
\hline
Beans (g) & 0.56 & 0.36 \\
\hline
Mean values & 0.59 & 0.38 \\
\hline
\end{tabular}}
\end{table}
|
PMC3092766_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
& \textbf{Morocco} & \textbf{Tunisia} \\
\hline
Magnitude of immigration & Low & High \\
\hline
Politicization of immigration & High & Low \\
\hline
Magnitude of political change & Low & High \\
\hline
\end{tabular}}
\end{table}
|
PMC5830462_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
D—H···A & D—H & H···A & D···A & D—H···A \\
\hline
N2—H2A···N1 & 0.86 & 2.67 & 3.300 (15) & 131 \\
\hline
\end{tabular}}
\end{table}
|
PMC3343968_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|}
\hline
& & \multicolumn{2}{|l|}{\textbf{Flow rate $\pm$ 0.02 (mL min−1)}} & \multicolumn{2}{|l|}{\textbf{pH $\pm$ 0.1}} & \multicolumn{2}{|l|}{\textbf{Mobile phase composition $\pm$ 2\% (Acetonitrile: Phosphate buffer)}} & \multicolumn{2}{|l|}{\textbf{Column oven temperature $\pm$ 2 °C}} \\
\hline
\textbf{Parameter} & \textbf{Optimized method} & \textbf{0.48} & \textbf{0.52} & \textbf{3.4} & \textbf{3.6} & \textbf{48\%: 52\%} & \textbf{52\%: 48\%} & \textbf{23 °C} & \textbf{27 °C} \\
\hline
Area under the peak, Recovery \% & 101.98 & 99.66 & 99.56 & 100.64 & 100.59 & 101.66 & 100.22 & 100.15 & 100.58 \\
\hline
Retention time, min & 1.86 & 1.84 & 1.85 & 1.89 & 1.85 & 1.87 & 1.86 & 1.88 & 1.85 \\
\hline
Peak height, mAU & 235.76 & 238.55 & 241.21 & 233.07 & 237.23 & 238.34 & 234.39 & 239.44 & 240.8 \\
\hline
\end{tabular}}
\end{table}
|
PMC5722889_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
Refinement on F2 & Primary atom site location: structure-invariant direct methods \\
\hline
Least-squares matrix: full & Secondary atom site location: difference Fourier map \\
\hline
R[F2 $>$ 2$\sigma$(F2)] = 0.029 & Hydrogen site location: difference Fourier map \\
\hline
wR(F2) = 0.073 & H atoms treated by a mixture of independent and constrained refinement \\
\hline
S = 1.04 & w = 1/[$\sigma$2(Fo 2) + (0.0349P)2 + 5.3131P] where P = (Fo 2 + 2Fc 2)/3 \\
\hline
9026 reflections & ($\Delta$/$\sigma$)max = 0.002 \\
\hline
531 parameters & $\Delta$$\rho$max = 2.02 e Å−3 \\
\hline
0 restraints & $\Delta$$\rho$min = −0.75 e Å−3 \\
\hline
\end{tabular}}
\end{table}
|
PMC3238708_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Parameter [statistic]} & \textbf{All patients} & \multicolumn{3}{|l|}{\textbf{Olanzapine vs. non-olanzapine}} & \multicolumn{3}{|l|}{\textbf{Risperidone vs. non-risperidone}} & \multicolumn{3}{|l|}{\textbf{Haloperidol vs. non-haloperidol}} \\
\hline
& & \textbf{OLZ (N = 390)} & \textbf{Non-OLZ (N = 168)} & \textbf{p-value} & \textbf{RIS (N = 72)} & \textbf{Non-RIS (N = 486)} & \textbf{p-value} & \textbf{HAL (N = 132)} & \textbf{Non-HAL (N = 426)} & \textbf{p-value} \\
\hline
& \textbf{(N = 558)} \\
\hline
\multicolumn{11}{|l|}{Previous pharmacological treatmenta} \\
\hline
Any previous medication n (\%) & 291 (52.2) & 191 (49.0) & 100 (59.5) & 0.022 & 45 (62.5) & 246 (50.6) & 0.060 & 64 (48.5) & 227 (53.3) & 0.335 \\
\hline
Any antipsychotic n (\%) & 214 (38.4) & 130 (33.3) & 84 (50.0) & $<$ .001 & 38 (52.8) & 176 (36.2) & 0.007 & 52 (39.4) & 162 (38.0) & 0.778 \\
\hline
Olanzapine, n (\%) & 52 (9.3) & 48 (12.3) & 4 (2.4) & & 5 (6.9) & 47 (9.7) & & 13 (9.8) & 39 (9.2) \\
\hline
Risperidone, n (\%) & 50 (9.0) & 26 (6.7) & 24 (14.3) & & 30 (41.7) & 20 (4.1) & & 11 (8.3) & 39 (9.2) \\
\hline
Haloperidol, n (\%) & 45 (8.1) & 30 (7.7) & 15 (8.9) & & 5 (6.9) & 40 (8.2) & & 25 (18.9) & 20 (4.7) \\
\hline
Quetiapine, n (\%) & 19 (3.4) & 6 (1.5) & 13 (7.7) & & 0 (0.0) & 19 (3.9) & & 4 (3.0) & 15 (3.5) \\
\hline
Any benzodiazepine n (\%) & 106 (19.0) & 75 (19.2) & 31 (18.5) & 0.830 & 10 (13.9) & 96 (19.8) & 0.236 & 22 (16.7) & 84 (19.7) & 0.435 \\
\hline
Lorazepam, n (\%) & 51 (9.1) & 36 (9.2) & 15 (8.9) & & 6 (8.3) & 45 (9.3) & & 14 (10.6) & 37 (8.7) \\
\hline
Diazepam, n (\%) & 43 (7.7) & 29 (7.4) & 14 (8.3) & & 3 (4.2) & 40 (8.2) & & 7 (5.3) & 36 (8.5) \\
\hline
Mood stabilizer n (\%) & 67 (12.0) & 48 (12.3) & 19 (11.3) & 0.939 & 7 (9.7) & 60 (12.3) & 0.568 & 11 (8.3) & 56 (13.1) & 0.141 \\
\hline
Antidepressants n (\%) & 64 (11.5) & 47 (12.1) & 17 (10.1) & 0.679 & 8 (11.1) & 56 (11.5) & 0.976 & 9 (6.8) & 55 (12.9) & 0.056 \\
\hline
Antipsychotic monotherapy n (\%) & 227 (40.7) & 183 (46.9) & 44 (26.2) & $<$ .001 & 13 (18.1) & 214 (44.0) & $<$ .001 & 11 (8.3) & 216 (50.7) & $<$ .001 \\
\hline
\multicolumn{11}{|l|}{Concomitant benzodiazepine use} \\
\hline
Any benzodiazepine use n (\%) [95\% CI (\%)] & 389 (69.7) [65.7–73.5] & 268 (68.7) [63.9–73.3] & 121 (72.0) [64.6–78.7] & 0.436 & 52 (72.2) [60.4–82.1] & 337 (69.3) [65.0–73.4] & 0.620 & 110 (83.3) [75.9–89.3] & 279 (65.5) [60.8–70.0] & $<$ .001 \\
\hline
Lorazepam, n (\%) & 248 (44.4) & 177 (45.4) & 71 (42.3) & & 35 (48.6) & 213 (43.8) & & 65 (49.2) & 183 (43.0) \\
\hline
Diazepam, n (\%) & 175 (31.4) & 109 (27.9) & 66 (39.3) & & 29 (40.3) & 146 (30.0) & & 75 (56.8) & 100 (23.5) \\
\hline
Other, n (\%) & 64 (11.5) & 38 (9.7) & 26 (15.5) & & 12 (16.7) & 52 (10.7) & & 12 (9.1) & 52 (12.2) \\
\hline
Benzodiazepine doseb mean (SD), mg & 81.3 (58.1) & 77.9 (52.5) & 89.0 (68.5) & 0.081 & 86.4 (72.5) & 80.6 (55.6) & 0.497 & 76.4 (50.6) & 83.3 (60.8) & 0.296 \\
\hline
\end{tabular}}
\end{table}
|
PMC2507712_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \textbf{U11} & \textbf{U22} & \textbf{U33} & \textbf{U12} & \textbf{U13} & \textbf{U23} \\
\hline
O001 & 0.0320 (5) & 0.0242 (4) & 0.0153 (4) & 0.0015 (4) & 0.0037 (4) & −0.0013 (3) \\
\hline
N2 & 0.0218 (5) & 0.0184 (4) & 0.0150 (4) & 0.0016 (4) & −0.0021 (4) & 0.0006 (3) \\
\hline
N1 & 0.0233 (5) & 0.0172 (4) & 0.0156 (4) & 0.0040 (4) & −0.0009 (4) & 0.0001 (4) \\
\hline
C8 & 0.0195 (5) & 0.0166 (5) & 0.0152 (5) & −0.0009 (4) & 0.0005 (4) & 0.0018 (4) \\
\hline
C2 & 0.0197 (5) & 0.0175 (5) & 0.0166 (5) & −0.0002 (4) & 0.0004 (4) & −0.0011 (4) \\
\hline
C6 & 0.0237 (6) & 0.0211 (5) & 0.0202 (5) & 0.0015 (5) & −0.0015 (5) & 0.0007 (4) \\
\hline
C11 & 0.0239 (6) & 0.0214 (5) & 0.0172 (5) & −0.0029 (5) & 0.0019 (5) & −0.0017 (4) \\
\hline
C13 & 0.0196 (5) & 0.0158 (4) & 0.0150 (5) & 0.0004 (4) & 0.0013 (4) & 0.0009 (4) \\
\hline
C12 & 0.0224 (5) & 0.0207 (5) & 0.0151 (5) & 0.0000 (4) & −0.0003 (4) & 0.0006 (4) \\
\hline
C1 & 0.0188 (5) & 0.0185 (5) & 0.0170 (5) & −0.0006 (4) & −0.0008 (4) & −0.0006 (4) \\
\hline
C9 & 0.0219 (5) & 0.0182 (5) & 0.0207 (5) & 0.0018 (4) & 0.0015 (5) & 0.0018 (4) \\
\hline
C4 & 0.0243 (6) & 0.0220 (6) & 0.0221 (6) & 0.0024 (5) & 0.0021 (5) & −0.0036 (4) \\
\hline
C3 & 0.0202 (5) & 0.0210 (5) & 0.0166 (5) & −0.0022 (4) & 0.0010 (4) & −0.0020 (4) \\
\hline
C5 & 0.0265 (6) & 0.0194 (5) & 0.0265 (6) & 0.0047 (5) & −0.0011 (5) & −0.0010 (5) \\
\hline
C10 & 0.0242 (6) & 0.0180 (5) & 0.0219 (5) & 0.0004 (5) & 0.0041 (5) & −0.0015 (4) \\
\hline
C7 & 0.0382 (7) & 0.0313 (7) & 0.0195 (5) & 0.0066 (6) & 0.0031 (5) & 0.0052 (5) \\
\hline
B1 & 0.0202 (5) & 0.0178 (5) & 0.0157 (5) & −0.0005 (5) & 0.0001 (5) & 0.0003 (4) \\
\hline
\end{tabular}}
\end{table}
|
PMC3394032_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
& & \textbf{Female* (n = 881)} & \textbf{Male* (n = 1781)} \\
\hline
\multicolumn{4}{|l|}{Sociodemographics} \\
\hline
\multicolumn{2}{|l|}{Median age, years (IQR)} & 28 (25–32) & 30 (28–34) \\
\hline
Education, n (\%) & No education & 2 (0.3) & 2 (0.2) \\
\hline
& Up to 6 years & 83 (11.3) & 44 (2.9) \\
\hline
& $>$6 to 9 years & 110 (14.9) & 136 (9.0) \\
\hline
& $>$9 to 12 years & 356 (48.3) & 799 (53.1) \\
\hline
& $>$12 years & 186 (25.2) & 524 (34.8) \\
\hline
Occupation, n (\%) & None & 163 (22.1) & 340 (22.5) \\
\hline
& Housewife & 299 (40.5) & 3 (0.2) \\
\hline
& Job in the past month & 277 (37.5) & 1166 (77.3) \\
\hline
Marital status, n (\%) & Single & 85 (11.6) & 669 (44.5) \\
\hline
& Married & 439 (59.7) & 709 (47.1) \\
\hline
& Divorced/widowed & 211 (28.7) & 126 (8.3) \\
\hline
Smoking, n (\%) & & 188 (35.7) & 776 (76.0) \\
\hline
\multicolumn{4}{|l|}{Probable transmission route} \\
\hline
History of IDU, n (\%) & & 112 (16.1) & 1081 (73.8) \\
\hline
History of sex work, n (\%) & & 14 (6.6) & 0 \\
\hline
\multicolumn{2}{|l|}{HIV test because of partner notification, n (\%)} & 54 (25.5) & 14 (4.0) \\
\hline
\multicolumn{4}{|l|}{Risk behaviour} \\
\hline
Condom use, n (\%) & Never & 337 (67.8) & 427 (56.1) \\
\hline
& Rarely & 33 (6.8) & 48 (6.4) \\
\hline
& Sometimes & 41 (8.3) & 66 (8.8) \\
\hline
& Often & 14 (2.8) & 51 (6.6) \\
\hline
& Always & 71 (14.3) & 170 (22.1) \\
\hline
\multicolumn{4}{|l|}{Clinical status} \\
\hline
WHO clinical stage, \% & I & 258 (39.6) & 179 (13.5) \\
\hline
& II & 58 (8.9) & 83 (6.3) \\
\hline
& III & 133 (20.4) & 399 (30.1) \\
\hline
& IV & 203 (31.1) & 663 (50.1) \\
\hline
\multicolumn{4}{|l|}{Laboratory parameters} \\
\hline
\multicolumn{2}{|l|}{Median CD4, cells/µl (IQR)} & 207 (51–370) & 81 (18–270) \\
\hline
\multicolumn{2}{|l|}{Positive anti-HCV Antibody, n (\%)} & 122 (22.8) & 868 (74.9) \\
\hline
Positive Hepatitis B, n (\%) & & 17 (2.9) & 96 (7.7) \\
\hline
\multicolumn{3}{|l|}{Reproductive health} & N/A \\
\hline
Pregnant, n (\%) & & 43 (8.6) \\
\hline
\multicolumn{2}{|l|}{Contraceptive use other than condom, n (\%)} & 120 (22.5) \\
\hline
Number of children, n (\%) & 0 & 179 (25.6) \\
\hline
& 1 & 320 (45.9) \\
\hline
& 2 & 142 (20.3) \\
\hline
& $\geq$3 & 57 (8.2) \\
\hline
\end{tabular}}
\end{table}
|
PMC4673839_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Strains} & \textbf{Identities/HSP length} & \textbf{Probability $>$ 70 \%} & \textbf{Probability $>$ 79 \%} \\
\hline
S. nematodiphila DSM 21420T & 57.90 \% $\pm$ 2.77 & 45.06 \% & 35.51 \% \\
\hline
S. marcescens LMG 2792T & 56.40 \% $\pm$ 2.75 & 39.98 \% & 8.95 \% \\
\hline
S. ureilytica Lr5-4 LG59 & 55.30 \% $\pm$ 2.72 & 35.95 \% & 7.86 \% \\
\hline
S. plymuthica S13 & 28.30 \% $\pm$ 2.43 & 0.05 \% & 0.02 \% \\
\hline
S. proteamaculans LMG 8751T & 27.20 \% $\pm$ 2.43 & 0.03 \% & 0.02 \% \\
\hline
S. symbiotica DSM 23270T & 27.00 \% $\pm$ 2.42 & 0.03 \% & 0.01 \% \\
\hline
S. liquefaciens LMG 7884T & 27.00 \% $\pm$ 2.42 & 0.03 \% & 0.01 \% \\
\hline
S. odorifera LMG 7885T & 25.10 \% $\pm$ 2.40 & 0.01 \% & 0.01 \% \\
\hline
S. fonticola LMG 7882T & 24.60 \% $\pm$ 2.40 & 0.01 \% & 0 \% \\
\hline
\end{tabular}}
\end{table}
|
PMC5094094_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Model parameters} & \textbf{Actinoplanes sp. SE50/110 (iYLW1028)} & \textbf{S. coelicolor A3(2) Borodina et al., 2005} & \textbf{M. tuberculosis H37Rv Jamshidi and Palsson, 2007} \\
\hline
\multicolumn{4}{|l|}{GENOME FEATURE} \\
\hline
Genome size (Mbp) & 9.24 & 8.7 & 4.41 \\
\hline
Total open reading frames & 8247 & 7825 & 3924 \\
\hline
G+C content (\%) & 71.36 & 72.12 & 65.6 \\
\hline
\multicolumn{4}{|l|}{GENOME-SCALE METABOLIC MODEL FEATURE} \\
\hline
Total reactions & 1219 & 699 & 936 \\
\hline
Biochemical transformations & 1091 & 560 & 843 \\
\hline
Transport reactions & 128 & 139 & 93 \\
\hline
Metabolites & 1128 & 500 & 740 \\
\hline
ORFs assigned in metabolic network & 1028 & 711 & 661 \\
\hline
ORF coverage (\%) & 12.5 & 9.1 & 16.8 \\
\hline
Compartments & 2 (c, e) & 2 (c, e) & 2 (c, e) \\
\hline
\end{tabular}}
\end{table}
|
PMC4479805_table_1
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Objective} & \textbf{Target} & \textbf{Size (bp)} & \textbf{Forward Primer (5′–3′)} & \textbf{Reverse Primer (3′–5′)} \\
\hline
TOPO$\circledR$ Cloning (standard curve) & COI & 356 & AGC CGT CAG AGA CAG TAA & CGT GAC CAA GCC CTA ATA AA \\
\hline
& ATP6 & 342 & GGT TGT TAC GTT AGG CTT GT & ACT TGA ATA ACC GCC ACT \\
\hline
& EF-1-$\alpha$ & 803 & TTC TCT CTT ACA CCC TTG G & CTT GTC AGT GGG TCT CTT \\
\hline
QPCR & COI & 101 & GTC TCC CAG CCG GAA ATA AA & ACC ATT GTC AGC ATC TCT CG \\
\hline
& ATP6 & 144 & CGT CTC GCC GCA AAT TTA TC & TGC GGC CTC TAG TAG ACT TA \\
\hline
& EF-1-$\alpha$ & 89 & AGC ACT GAG CCA CCA TAC AG & TTG GGT TAT AGC CGG TCT TC \\
\hline
\end{tabular}}
\end{table}
|
PMC4834350_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Topics} & \textbf{Learning objectives (At the end of this workshop the students will be able to …)} & \textbf{Learning activities} & \textbf{Approximate time (min)} \\
\hline
Introduction & … describe the importance and objectives of empathy-building workshop & Lecture & 15 \\
\hline
Epidemiology of aging & … describe epidemiology of aging & Lecture & 20 \\
\hline
Physiological and psychological changes of aging & … explain physiological and psychological changes of aging & Lecture, question and answer & 60 \\
\hline
Common barriers to communication in older adults & … explain barriers to communication in older adults & Lecture, group discussion, Clip presentation & 30 \\
\hline
Exercise on communication & … analyze challenges and their own experiences in communication with elderly people & - Three scenarios were presented: - The students were asked to identify and discuss the challenges in the scenarios - Encouraged students to discuss their experiences of similar situations with elderly people - Giving feedback and summing up & 40 \\
\hline
Interactions between healthcare professionals and older patients & … interact professionally with older patients in a simulated situation & Role play on listening skills, lecture, group discussion & 60 \\
\hline
Definition of self-awareness and its importance & ... discuss self-awareness and its importance & Lecture and group discussion & 30 \\
\hline
Exercise on self-awareness & … identify their own attitudes toward aging and its impact on their communication with elder patients & -The students were asked to identify their feelings and attitudes toward aging and its impact on their communication with elderly patients -Giving feedback and summing up & 45 \\
\hline
Empathy skills, understanding, listening, accepting others, etc. & … explain empathy skills and their importance & Lecture and group discussion & 90 \\
\hline
Exercise on empathy skills & …discuss empathetic behaviors and lack of empathy in nurse-patient relationship ….identify their own barriers and abilities to show empathy toward older adults & - Presenting one scenario and two short clips about empathy with elderly patients -Asking students to discuss the scenario within their groups and identify empathic or lack of empathic behaviors. - Giving feedback and summing up & 90 \\
\hline
\end{tabular}}
\end{table}
|
PMC6094453_table_0
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Mediator} & \textbf{Estimate} & \textbf{95\% CI} \\
\hline
\multicolumn{3}{|l|}{Mothers} \\
\hline
Hyperarousal & 0.084 & 0.011–0.222 \\
\hline
Internal avoidance & -0.011 & -0.058–0.004 \\
\hline
External avoidance & 0.001 & -0.043–0.054 \\
\hline
\multicolumn{3}{|l|}{Fathers} \\
\hline
Hyperarousal & -0.022 & -0.100–0.007 \\
\hline
Internal avoidance & 0.003 & -0.016–0.043 \\
\hline
External avoidance & -0.042 & -0.142–0.011 \\
\hline
\end{tabular}}
\end{table}
|
PMC4871492_table_2
|
|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{2009 (H1N1) Influenza CAP (n = 22)} & \textbf{CAP, other Etiology (n = 291)} & \textbf{Odds ratio (95\% CI)} & \textbf{P valuea} \\
\hline
\multicolumn{5}{|l|}{Therapy, No. (\%)} \\
\hline
IV abx therapy & 22 (100) & 291 (100) \\
\hline
oseltamivir & 19 (86) \\
\hline
Atypical coverageb & 15 (68) & 111 (38) & 3.53 (1.39–8.92) & .01 \\
\hline
Duration of abx, mean (CI), days & 14.3 (8.5–20.2) & 11.5 (11.0–11.9) & & .75 \\
\hline
Length of stay, mean (CI),days & 9.6 (6.2–13.0) & 7.4 (6.8–7.9) & & .13 \\
\hline
ICU admission & 9 (41) & 16 (5) & 11.7 (4.4–31.5) & ,.001 \\
\hline
Invasive ventilation & 3 (14) & 5 (2) & 9.03 (2.01–40.67) & .01 \\
\hline
In-hospital mortality & 0 (0) & 10 (3) & .96 (.94–.99) \\
\hline
\multicolumn{5}{|l|}{Etiologic testing, No (\%)} \\
\hline
Sputum acquired & 10 (45) & 147 (51) & .83 (.35–1.98) & .83 \\
\hline
Representive sputum acquired & 5 (23) & 97 (33) & .60 (.21–1.67) & .48 \\
\hline
Blood culture & 22 (100) & 211 (73) & .73 (.68–.78) & .002 \\
\hline
BAL & 1 (5) & 8 (3) & 1.69 (.20–14.11) & .49 \\
\hline
UAT S. pneumoniae & 15 (68) & 210 (72) & .83 (.33–2.10) & .81 \\
\hline
UAT L. pneumophila & 13 (59) & 197 (68) & .69 (.29–1.67) & .48 \\
\hline
\end{tabular}}
\end{table}
|
PMC3469650_table_2
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.